

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDING DECEMBER 31, 2014 OF THE CONDITION AND AFFAIRS OF

Aetna Health Inc. (a Maine corporation)

NAIC Group Code (Cui		0001 (Prior Period)	NAIC Company Co	de 95517	Employer's ID Number	01-0504252
Organized under the Laws	s of Maine	St	ate of Domicile or Port of E	ntry Maine	Country of Domicile	United States
Licensed as business type:	Life, Accide	ent & Health []	Property/Casual	ty []	Hospital, Medical & Dental Service of	
		vice Corporation	[] Vision Service C	Corporation []	• • • • • • • • • • • • • • • • • • • •	
	Other []			ly Qualified? Yes [
Incorporated/Organized		. October 3, 1	995	Comr	nenced Business April 10, 1 . South Portland ME US 04	1996
Statutory Home Office		1/5 F		01		
Main Administration Office	_		(Street and Number)	1	(City, State, Country, and Zip Co	oae)
Main Administrative Office	······		980 Jolly Ro			
	Diva	Dall DA	(Street and Nu		800-872-3862	
Mail Addraga			try, and Zip Code)		(Area Code) (Telephone Number) Blue Bell PA US 19422	4004
Mail Address			Street and Number or P. O.		(City, State, Country, and Zip Co	
Drimany Location of Pooks	and Door	,	980 Jolly R	,	(Oity, State, Country, and Zip Co	Jue)
Filliary Location of Books	s and Necoi	us	Street and Nu			
	Plus	Pall DA	US 19422-1904		900 972 2962	
			03 19422-1904 try, and Zip Code)	•••••	(Area Code) (Telephone Number)	
Internet Weheite Address			www.aetna.c	om	(Area Code) (Telephone Number)	
					215-775-6508	
Statutory Statement Conto	act		Dawn Marie Schoen (Name)		(Area Code) (Telephone Numbe	or) (Extension)
		Aotna H				i) (Exterision)
		Actila.ii	(E-mail Address)		(Fax Number)	
Martha Reardon Temp Edward Chung-I Lee, Dawn Marie Schoen, I	Vice Presid	lent and Secr		RS OTHER	Elaine Rose Cofrancesco, Treasure Gregory Stephen Martino, Vice Pres Kevin James Casey, Senior Investn Brian Christopher Winters, Assista	sident nent Officer
Dobort Konn	oth Downs		DIRECTORS OR		Martha Daardan Ta	
Robert Kenn	ieth Downs		David Bradle	ey worse	Martha Reardon Te	mpie
stated above, all of the hereistated, and that this stateme the assets and liabilities and for the period ended, and ha to the extent that: (1) state is according to the best of the related corresponding electrons	n described a ent, together if of the conditive been com law may differ ir information onic filing wit	assets were the with related exhi- ion and affairs of pleted in accord er; or, (2) that si , knowledge an h the NAIC, wh	absolute property of the said re ibits, schedules and explanation of the said reporting entity as of ance with the NAIC Annual State tate rules or regulations required belief, respectively. Further	eporting entity, free ons therein contain of the reporting peri- atement Instruction re differences in re- more, the scope of copy (except for fo	cers of said reporting entity, and that on the and clear from any liens or claims thereon, ed, annexed or referred to, is a full and true of stated above, and of its income and ded is and Accounting Practices and Procedures porting not related to accounting practices of this attestation by the described officers rematting differences due to electronic filing seed statement.	except as herein e statement of all uctions therefrom s manuals except and procedures, also includes the
(Signature)		(Signature)		(Signature)	
Martha Reardon	n Temple		Edward Chung-		Dawn Marie Scho	
President			Vice President and	Secretary@	Principal Financial Officer and	i Controller@@
State ofConnecticut			State of Connecticut		State of Pennsylvania	
County of Hartford			County of Hartford		County of Montgomery	
Subscribed and sworn to before	me this		@Subscribed and sworn to before	e me this	@@Subscribed and sworn to before	o mo thio
day of		2015	<u> </u>		2015 day of Februa	e me uns ry 2015

NOTARY PUBLIC (Seal)

NOTARY PUBLIC (Seal)

NOTARY PUBLIC (Seal)

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) ASSETS

	710		Current Year		Prior Year
		1	2	3 Net Admitted	4
			Nonadmitted	Assets	Net
	Devile (Orbert Iv D)	Assets	Assets	(Cols. 1 - 2)	Admitted Assets
1.	Bonds (Schedule D): Stocks (Schedule D):		0	18,966,006	24,937,774
2.	2.1 Preferred stocks	0	0	0	0
			0		
,			0	0	0
3.	Mortgage loans on real estate (Schedule B): 3.1 First liens		0	0	
	3.2 Other than first liens	. 0	0	0	0
4.	Real estate (Schedule A): 4.1 Properties occupied by the company (less \$0 encumbrances)	0	0	0	0
	4.2 Properties held for the production of income (less \$0 encumbrances)				
	4.3 Properties held for sale (less \$0 encumbrances)				
5.	Cash (\$0, Schedule E-Part 1), cash equivalents (\$3,801,264, Schedule E-Part 2) and short-term investments (\$1,962, Schedule DA)				
6.	Contract loans (including \$0 premium notes)				
7.	Derivatives (Schedule DB)				
8.	Other invested assets (Schedule BA)				
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)		Î		
13.	Title plants less \$0 charged off (for Title insurers only)				
14.	Investment income due and accrued				
15.	Premiums and considerations:	,			,
	15.1 Uncollected premiums and agents' balances in the course of collection	3,292,812	83,728	3,209,084	2.804,537
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$0 earned but unbilled premiums)				0
	15.3 Accrued retrospective premiums		0	0	0
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers	0	0	0	0
	16.2 Funds held by or deposited with reinsured companies		0	0	0
	16.3 Other amounts receivable under reinsurance contracts		0	0	0
17.	Amounts receivable relating to uninsured plans	1,052,494	0	1,052,494	0
18.1	Current federal and foreign income tax recoverable and interest thereon		0	0	0
18.2	Net deferred tax asset	154,787	52,984	101,803	985,089
19.	Guaranty funds receivable or on deposit		0	0	0
20.	Electronic data processing equipment and software				
21.	Furniture and equipment, including health care delivery assets (\$0)				
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$221,447) and other amounts receivable				
25.	Aggregate write-ins for other than invested assets				
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)				
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts		0	0	0
28.	TOTALS (Lines 26 and 27)	28,044,874	136,712	27,908,162	34,153,288
-	DETAILS (OF WRITE-INS			
			0		
	Summary of remaining write-ins for Line 11 from overflow page		0		
	Summary of remaining write-ins for Line 11 from overflow page Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)				
	Other Receivable		0		
	Current State Income Tax Receivable	· .	0		·
	Pharmacy Manufacturer"s Discount Receivable		0		
	Summary of remaining write-ins for Line 25 from overflow page		0		
2599	. Totals (Lines 2501 thru 2503 plus 2598) (Line 25 above)	. 429,694	0	429,694	417,185

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) LIABILITIES, CAPITAL AND SURPLUS

	; ,		Prior Year		
		1 Covered	2 Uncovered	3 Total	4 Total
_	Claims was aid (loss © 42 404 missources and all)				
1.	Claims unpaid (less \$43,191 reinsurance ceded)				
2.	Accrued medical incentive pool and bonus amounts	·		•	•
3.	Unpaid claims adjustment expenses	146,908	0	146,908	169,805
4.	Aggregate health policy reserves, including the liability of \$48 for medical loss ratio rebate per the Public Health Service Act	27.002	0	27.002	2.150.042
5.	Aggregate life policy reserves				
6.	Property/casualty unearned premium reserve				
7.	Aggregate health claim reserves				
8.	Premiums received in advance				
9.	General expenses due or accrued	364,405	0	364,405	31,666
10.1	Current federal and foreign income tax payable and interest thereon (including \$0 on realized capital gains (losses))	36,662	0	36,662	232,853
10.2	Net deferred tax liability	0	0	0	0
11.	Ceded reinsurance premiums payable	0	0	0	0
12.	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated				
14.	Borrowed money (including \$0 current) and interest thereon \$0 (including \$0 current)				
45	Amounts due to parent, subsidiaries and affiliates				
15.	·				
16.	Derivatives				
17.	Payable for securities.				
18.	Payable for securities lending	0	0	0	0
19.	Funds held under reinsurance treaties with (\$0 authorized reinsurers, \$43,191 unauthorized and \$0 certified reinsurers)				
20.	Reinsurance in unauthorized and certified (\$0) companies	0	0	0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates	0	0	0	0
22.	Liability for amounts held under uninsured plans	0	0	0	0
23.	Aggregate write-ins for other liabilities (including \$0 current)	268,678	0	268,678	157,859
24.	Total liabilities (Lines 1 to 23)				
25.	Aggregate write-ins for special surplus funds	XXX	XXX	2.000.000	0
26.	Common capital stock				
27.	Preferred capital stock				
	Gross paid in and contributed surplus				
28.	Surplus notes				
29.					
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)	XXX	XXX	3,969,848	4,208,387
32.	Less treasury stock at cost:				
	32.10.000 shares common (value included in Line 26 \$).	XXX	XXX	0	0
	32.20.000 shares preferred (value included in Line 27 \$0)	XXX	XXX	0	0
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	15,669,848	13,908,387
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	27,908,162	34,153,288
	DETAILS	OF WRITE-INS			
2301.	CMS Coverage Gap Discount	260,388	0	260,388	51,579
	CMS Payable				
	Medicare Part D Low Income Cost Share Payable				
	Summary of remaining write-ins for Line 23 from overflow page				
	Totals (Lines 2301 thru 2303 plus 2398) (Line 23 above)				
	Estimated 2015 Health Insurer Fee Accrual				
	Summary of remaining write-ins for Line 25 from overflow page				
	Totals (Lines 2501 thru 2503 plus 2598) (Line 25 above)				
	\				
	Summary of remaining write-ins for Line 30 from overflow page				
	Totals (Lines 3001 thru 3003 plus 3098) (Line 30 above)				
0000.	Totalo (Elito oco i tilla ocoo piao ocoo) (Elite oc above)	/v\/\	/VV\	U	U

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) STATEMENT OF REVENUE AND EXPENSES

		Current Y		Prior Year
		1 Uncovered	2 Total	3 Total
1.	Member months	XXX	205,808 .	210,993
2.	Net premium income (including \$0 non-health premium income)	XXX	104,695,049	98,180,276
3.	Change in unearned premium reserves and reserve for rate credits	XXX	22,018	98,675
4.	Fee-for-service (net of \$0 medical expenses)			
5.	Risk revenue			
6.	Aggregate write-ins for other health care related revenues			
7.	Aggregate write-ins for other non-health revenues			
8.	Total revenues (Lines 2 to 7)			
_	ital and Medical:			
9.	Hospital/medical benefits	1 687 500	71 438 197	64 770 798
10.	Other professional services		0	
11.	Outside referrals		1,208,173	
12.	Emergency room and out-of-area		3,749,835	
	Prescription drugs		14,255,448	
13.	, ,		0	
14.	Aggregate write-ins for other hospital and medical			-
15.	Incentive pool, withhold adjustments and bonus amounts			
16.	Subtotal (Lines 9 to 15)		91,536,094	84,450,948
Less				
17.	Net reinsurance recoveries			
18.	Total hospital and medical (Lines 16 minus 17)			
19.	Non-health claims (net)		0	
20.	Claims adjustment expenses, including \$1,147,741 cost containment expenses			
21.	General administrative expenses		12,084,100	11,010,883
22.	Increase in reserves for life and accident and health contracts including \$0		(0.440.500)	0.000.000
	increase in reserves for life only)			
23.	Total underwriting deductions (Lines 18 through 22)			
24.	Net underwriting gain or (loss) (Lines 8 minus 23)			
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)			
26.	Net realized capital gains or (losses) less capital gains tax of \$44,397			
27.	Net investment gains or (losses) (Lines 25 plus 26)	0	718,033	(150,793)
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$0) (amount charged off \$0)]			0
29.	Aggregate write-ins for other income or expenses	0	0	0
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	xxx	2,816,220	(1,791,276)
31.	Federal and foreign income taxes incurred	XXX	256,566	(425,705)
32.	Net income (loss) (Lines 30 minus 31)	XXX	2,559,654	(1,365,571)
	DETAILS OF WRIT	E-INS		
				0
				0
	Summary of remaining write-ins for Line 6 from overflow page			0
	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)			
	Totals (Ellios oct 1 and octo plus octo) (Ellio Vasoro).			0
				0
	Summary of remaining write-ins for Line 7 from overflow page			
	Totals (Lines 0701 thru 0703 plus 0798) (Line 7 above)		0 .	
			-	0
1402. 1403.				0
	Summary of remaining write-ins for Line 14 from overflow page		_	0
	Totals (Lines 1401 thru 1403 plus 1498) (Line 14 above)			0
				0
2902.		0		0
2903.			· ·	0
	Summary of remaining write-ins for Line 29 from overflow page			0
2999.	Totals (Lines 2901 thru 2903 plus 2998) (Line 29 above)	. [0]	0 .	0

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) STATEMENT OF REVENUE AND EXPENSES (Continued)

		1	2
	CAPITAL AND SURPLUS ACCOUNT	Current Year	Prior Year
33.	Capital and surplus prior reporting period	13,908,387	14,818,026
34.	Net income or (loss) from Line 32	2,559,654	(1,365,571)
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
36.	Change in net unrealized capital gains and (losses) less capital gains tax of \$0.	0	0
37.	Change in net unrealized foreign exchange capital gain or (loss)	0	0
38.	Change in net deferred income tax	(936,390)	650,521
39.	Change in nonadmitted assets	105,676	(194,589)
40.	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles	0	0
44.	Capital changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders	0	0
47.	Aggregate write-ins for gains or (losses) in surplus	32,521	0
48.	Net change in capital and surplus (Lines 34 to 47)	1,761,461	(909,639)
49.	Capital and surplus end of reporting period (Line 33 plus 48)	15,669,848	13,908,387
	DETAILS OF WRITE-INS		
4701.	Correction of Prior Period Prescription Drugs	50,033	0
4702.	Correction of Prior Period Federal Income Taxes Incurred	(17,512)	0
4703.		0	0
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798) (Line 47 above)	32,521	0

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) CASH FLOW

		1 Current Year	2 Prior Year
	CASH FROM OPERATIONS	Current real	FIIOI Teal
1.	Premiums collected net of reinsurance	104,333,068	97,150,412
2.	Net investment income.		517,366
3.	Miscellaneous income	, ,	(178,460)
4.	Total (Lines 1 through 3)		97,489,318
5.	Benefit and loss related payments		82,745,324
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		0
7.	Commissions, expenses paid and aggregate write-ins for deductions		13,392,568
8.	Dividends paid to policyholders		0
9.	Federal and foreign income taxes paid (recovered) net of \$0 tax on capital gains (losses)		(1,443,458)
10.	Total (Lines 5 through 9)		94,694,434
11.	Net cash from operations (Line 4 minus Line 10)		
	CASH FROM INVESTMENTS	(=,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	_,, ,
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds	6,144,174	703,068
	12.2 Stocks		0
	12.3 Mortgage loans		0
	12.4 Real estate		0
	12.5 Other invested assets		0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	63	15
	12.7 Miscellaneous proceeds		3,935,836
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	6,144,237	4,638,919
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds		8,054,430
	13.2 Stocks		0
	13.3 Mortgage loans		0
	13.4 Real estate		0
	13.5 Other invested assets		0
	13.6 Miscellaneous applications	3,935,836	0
	13.7 Total investments acquired (Lines 13.1 to 13.6)	3,935,836	8,054,430
14.	Net increase (decrease) in contract loans and premium notes		0
15.	Net cash from investments (Line 12.8 minus Lines 13.7 minus Line 14)	2,208,401	(3,415,511)
	CASH FROM FINANCING AND MISCELLANEOUS SOURCES		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes.		0
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)		
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	, , ,	, , , , ,
18.	Net change in cash, cash equivalents and short-term investments (Line 11 plus Line 15 plus Line 17)	(770.377)	(1.020.794)
19.	Cash, cash equivalents and short-term investments:		(1,020,104)
	19.1 Beginning of year	4 573 603	5 594 397
	19.2 End of year (Line 18 plus Line 19.1)		
NI a f			4 ,573,003
Note:	Supplemental disclosures of cash flow information for non-cash transactions:	1 01	

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation)

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

	1	2	3	4	5	6	7	8	9	10
	Total	Comprehensive (Hospital and Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plans	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
Net premium income	104,695,049	42,936,964	0	0	0	0	61,758,085	0	0	0
Change in unearned premium reserves and reserve for rate credit	22,018	22,018	0	0	0	0	0	0	0	0
3. Fee-for-service (net of \$0 medical expenses)	0	0	0	0	0	0	0	0	0	XXX
4. Risk revenue	0	0	0	0	0	0	0	0	0	XXX
Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	XXX
Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
7. Total revenues (Lines 1 to 6)	104,717,067	42,958,982	0	0	0	0	61,758,085	0	0	0
8. Hospital/medical benefits	71,438,197	25,534,592	0	0	0	0	45,903,605	0	0	XXX
Other professional services	0	0	0	0	0	0	0	0	0	XXX
10. Outside referrals	1,208,173	388,717	0	0	0	0	819,456	0	0	XXX
11. Emergency room and out-of-area	3,749,835	1,974,297	0	0	0	0	1,775,538	0	0	XXX
12. Prescription drugs	14,255,448	6,555,240	0	0	0	0	7,700,208	0	0	XXX
13. Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	XXX
14. Incentive pool, withhold adjustments and bonus amounts	884,441	313,662	0	0	0	0	570,779	0	0	XXX
15. Subtotal (Lines 8 to 14)	91,536,094	34,766,508	0	0	0	0	56,769,586	0	0	XXX
16. Net reinsurance recoveries	473,144	0	0	0	0	0	473,144	0	0	XXX
17. Total hospital and medical (Lines 15 minus 16)	91,062,950	34,766,508	0	0	0	0	56,296,442	0	0	XXX
18. Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
19. Claims adjustment expenses including \$1,147,741 cost containment expenses	1,591,423	727,850	0	0	0	0	863,573	0	0	0
20. General administrative expenses	12,084,100	6,642,772	0	0	0	0	5,441,328	0	0	0
21. Increase in reserves for accident and health contracts	(2,119,593)	(2,119,593)	0	0	0	0	0	0	0	XXX
22. Increase in reserve for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23. Total underwriting deductions (Lines 17 to 22)	102,618,880	40,017,537	0	0	0	0	62,601,343	0	0	0
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	2,098,187	2,941,445	0	0	0	0	(843,258)	0	0	0
			DETAILS OF W	RITE-INS						
0501	0	0	0	0	0	0	0	0	0	XXX
0502	0	0	0	0	0	0	0	0	0	XXX
0503	0	0	0	0	0	0	0	0	0	XXX
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	XXX
0599. Total (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	XXX
0601	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0602	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0603.	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0698. Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699. Total (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301	0	0	0	0	0	0	0	0	0	XXX
1302	0	0	0	0	0	0	0	0	0	XXX
1303	0	0	0	0	0	0	0	0	0	XXX
1398. Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0	0	0	0	0	0	XXX
1399. Total (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	XXX

PART 1 - PREMIUMS

_	TAKI I - I KEMIOMO		·		
		1	2	3	4
					Net Premium
		Direct	Reinsurance	Reinsurance	Income
	11. (2)				
	Line of Business	Business	Assumed	Ceded	(Cols. 1 + 2 - 3)
	Comprehensive (hospital and medical)	42,936,964	0	0	42,936,964
١.	Medicare supplement	0	0	0	0
١.	weducate supplierite	0		0	U
;	3. Dental only	0	0	0	0
	Vision only	0	n	0	0
١.	vision only	0	0	0	0
	5. Federal employees health benefits plan	0	0	0	0
	2 Tille Willi Medicare	62.231.229	0	473 144	61,758,085
	6. Title XVIII - Medicare	02,231,229		473,144	61,758,085
	7. Title XIX - Medicaid	0	0	0	0
	3. Other health	^	^	^	^
	3. Other health	0	U		U
	9. Health subtotal (Lines 1 through 8)	105,168,193	0	473,144	104,695,049
>		·			
	0. Life	0	n	0	0
	U. LIG	0			0
1	1. Property/casualty	0	0	0	0
	2. Totals (Lines 9 to 11)	105,168,193	1	473,144	104,695,049
L	Z. 10(a)s (Lilies 3 to 11)	100, 100, 193	JU	473,144	104,093,049

PART 2 - CLAIMS INCURRED DURING THE YEAR

	PART 2 - CLAIMS INCORRED DURING THE TEAR									
	1	2	3	4	5	6 Federal	7	8	9	10
	Total	Comprehensive (Hospital and Medical)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
Payments during the year:				•						
1.1 Direct	92,748,866	37,472,603	0	0	0	0	55,276,263	0	0	
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
1.3 Reinsurance ceded	429,953	0	0	0	0	0	429,953	0	0	
1.4 Net	92,318,913	37,472,603	0	0	0	0	54,846,310	0	0	
Paid medical incentive pools and bonuses	651,688	202,248	0	0	0	0	449,440	0	0	
3. Claim liability December 31, current year from Part 2A:	,,,,,,	, ,					, , ,			
3.1 Direct.	7,159,621	2,549,012	0	0	0	0	4,610,609	0	0	
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
3.3 Reinsurance ceded	43,191	0	0	0	0	0	43,191	0	0	
3.4 Net	7,116,430	2,549,012	0	0	0	0	4,567,418	0	0	(
Claim reserve December 31, current year from Part 2D:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,									
4.1 Direct	26,940	26,940	0	0	0	0	0	0	0	
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
4.4 Net	26,940	26,940	0	0	Λ	0	Λ	0	0	
Accrued medical incentive pools and bonuses, current year	464,125	111,414		0	0	0	352,711	0	0	
Net healthcare receivables (a)	118,579	47,038	0	0		0	71.541	0	0	
Amounts recoverable from reinsurers December 31, current year	n	47,030		٥		0	n71,341		Λ	
Claim liability December 31, prior year from Part 2A:		0	0	0	0	0			0	
8.1 Direct	9,110,256	5,493,732	0	0	0	0	3,616,524	,	_	,
8.2 Reinsurance assumed	9,110,230	5,495,752	0		0	0	0,010,024			
8.3 Reinsurance ceded.			0		0	0				
	9,110,256	5,493,732	0		0	0	3,616,524			
8.4 Net 9. Claim reserve December 31, prior year from Part 2D:	9,110,230		0	U	U	0	3,010,524	0	0	
	54,939	54,939	0	0	0	0			0	
9.1 Direct	54,939	54,939	0	0	0	0	0	0	0	
		0		0	0		0	0	0	
9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
9.4 Net	54,939	54,939	0	0	0	0	0	0	0	
10. Accrued medical incentive pools and bonuses, prior year	231,372	0	0	0	0	0	231,372	0	0	
11. Amounts recoverable from reinsurers December 31, prior year		0	0	<u></u> 0	0	0	0	0	10	(
12. Incurred benefits:	00.05/.555	04.450.515	_	_			50.405.55-	_		_
12.1 Direct	90,651,653	34,452,846	0	0]0	0	56,198,807]0]0	J
12.2 Reinsurance assumed	0	0	0	0]0	0	0	0]0	[
12.3 Reinsurance ceded	473,144	0	0	0	0	0	473,144	0	0	
12.4 Net	90,178,509	34,452,846	0	0	0	0	55,725,663	0	0	(
13. Incurred medical incentive pools and bonuses	884,441	313,662	0	0	0	0	570,779	0	0	(

⁽a) Excludes \$......0 loans or advances to providers not yet expensed.

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

		.,,	IXI ZA - CLAING							
	1	2 Comprehensive (Medical	3 Medicare	4 Dental	5 Vision	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9 Other	10 Other
	Total	and Hospital)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Health	Non-Health
Reported in process of adjustment: 1.1 Direct	1,539,021	1,064,698	0	0	0		474,323	0	0	0
1.4 Net	1,539,021	4 004 000	0		0	0	474 323			
Incurred but unreported: 2.1 Direct.	, ,	1,064,698		0	0		474,323			
	.,,		-	0	0	0	4,130,200	0	0	
2.2 Reinsurance assumed		0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	43,191	0	0	0	0	0	43,191	0	0	0
2.4 Net	5,577,409	1,484,314	0	0	0	0	4.093.095	l n	0	1
3. Amounts withheld from paid claims and capitations: 3.1 Direct	0	000	000	000	000	0	0 0 0		0	
4. Totals:										
4.1 Direct	,,.	2,549,012	0	0	0	0	4,610,609	0	0	(
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
4.3 Reinsurance ceded	43,191	0	0	0	0	0	43,191	0	0	C
4.4 Net	7.116.430	2,549,012	0	0	0	0	4.567.418	0	0	

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claim		Claim Reserve a	nd Claim Liability	5	6
	During t		December 31	of Current Year		Estimated Claim
	On Claims Incurred	2 On Claims	On Claims Unpaid	4 On Claims	Claims Incurred	Reserve and Claim Liability
	Prior to January 1	Incurred During	December 31 of	Incurred During	in Prior Years	December 31 of
Line of Business	of Current Year	the Year	Prior Year	the Year	(Columns 1 + 3)	Prior Year
Line of Dustriess	or ourtent rear	the real	Thorrea	the real	(Oolulling 1 · O)	Thorrea
Comprehensive (hospital and medical)	5,077,591	32,395,012	81,926	2,494,026	5,159,517	5,548,671
Medicare supplement	0	0	0	0	0	0
3. Dental only	0	0	0	0	0	0
4. Vision only	0	0	0	0	0	0
Federal employees health benefits plan	0	0	0	0	0	0
6. Title XVIII - Medicare	2,725,539	52,120,771	56,431	4,510,987	2,781,970	3,616,524
7. Title XIX - Medicaid	0	0	0	0	0	0
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)	7,803,130	84,515,783	138,357	7,005,013	7,941,487	9,165,195
10. Healthcare receivables (a)	0	221,447	0	0	0	102,868
11. Other non-health			0	0	0	0
12. Medical incentive pools and bonus amounts	0	651,688	36,547	427,578	36,547	231,372
13. Totals (Lines 9 - 10 + 11 + 12)	7,803,130	84,946,024	174,904	7,432,591	7,978,034	9,293,699

⁽a) Excludes \$......0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED CLAIMS

(000 Omitted)

SECTION A - PAID HEALTH CLAIMS - GRAND TOTAL

	Cumulative Net Amounts Paid								
Year in Which Losses	1	2	3	4	5				
Were Incurred	2010	2011	2012	2013	2014				
1. Prior	8,455	8,370	8,389	8,395	8,395				
2. 2010	65,229	70,518	70,500	70,531	70,561				
3. 2011	XXX	52,949	58,306	58,370	58,627				
4. 2012	XXX	XXX	66,391	73,836	73,966				
5. 2013	XXX	XXX	XXX	75,096	82,482				
6. 2014	XXX	XXX	XXX	XXX	84,946				

SECTION B - INCURRED HEALTH CLAIMS - GRAND TOTAL

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year										
	Year in Which Losses	1	2	3	4	5					
2	Were Incurred	2010	2011	2012	2013	2014					
G	1. Prior	9,294	8,451	8,441	8,395	8,395					
-	2. 2010	72,036	71,003	70,550	70,563	70,561					
	3. 2011	XXX	59,021	58,372	58,428	58,649					
	4. 2012	XXX	XXX	73,951	74,195	74,008					
	5. 2013	XXX	XXX	XXX	84,044	82,593					
	6. 2014	XXX	XXX	XXX	XXX	92,378					

SECTION C - INCURRED YEAR HEALTH CLAIM AND CLAIM ADJUSTMENT EXPENSE RATIO - GRAND TOTAL

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in Which					Adjustment			Unpaid Claim	Claims Adjustment	
	Premiums were Earned and	Premiums	Claim	Claim Adjustment	Percent	Expense Payments	Percent	Claims	Adjustment	Expense Incurred	Percent
	Claims were Incurred	Earned	Payments	Expense Payments	(Col. 3/2)	(Col. 2 + 3)	(Col. 5/1)	Unpaid	Expense	(Col. 5 + 7 + 8)	(Col. 9/1)
1.	2010	81,739	70,561	1,733	2.5	72,294	88.4	0	0	72,294	88.4
2.	. 2011	72,746	58,627	1,585	2.7	60,212	82.8	22	1	60,235	82.8
3.	. 2012	93,219	73,966	1,976	2.7	75,942	81.5	42	1	75,985	81.5
4.	. 2013	98,279	82,482	2,304	2.8	84,786	86.3	111	2	84,899	86.4
5.	2014	104,717	84,946	1,473	1.7	86,419	82.5	7,432	143	93,994	89.8

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED CLAIMS

(000 Omitted)

SECTION A - PAID HEALTH CLAIMS - HOSPITAL AND MEDICAL

	Cumulative Net Amounts Paid						
Year in Which Losses	1	2	3	4	5		
Were Incurred	2010	2011	2012	2013	2014		
1. Prior	7,635	7,543	7,554	7,560	7,560		
2. 2010	48,983	52,796	52,779	52,807	52,838		
3. 2011	XXX	37,659	41,574	41,630	41,889		
4. 2012	XXX	XXX	43,426	48,807	48,954		
5. 2013	XXX	XXX	XXX	40,699	45,340		
6. 2014	XXX	XXX	XXX	XXX	32,548		

SECTION B - INCURRED HEALTH CLAIMS - HOSPITAL AND MEDICAL

		Sum of Cumu	lative Net Amount Paid and Claim Liabilit	y, Claim Reserve and Medical Ince	ntive Pool and Bonuses Outstanding at End o	f Year
	Year in Which Losses	1	2	3	4	5
12	Were Incurred	2010	2011	2012	2013	2014
Ξ	1. Prior	8,445	7,616	7,601	7,560	7,560
Z	2. 2010	54,333	53,166	52,818	52,831	52,838
	3. 2011	XXX	41,633	41,627	41,677	41,903
	4. 2012	XXX	XXX	48,765	49,053	48,980
	5. 2013	XXX	XXX	XXX	45,931	45,382
	6. 2014	XXX	XXX	XXX	xxx	35,153

SECTION C - INCURRED YEAR HEALTH CLAIM AND CLAIM ADJUSTMENT EXPENSE RATIO - HOSPITAL AND MEDICAL

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in Which					Adjustment			Unpaid Claim	Claims Adjustment	
Premiums were Earned and	Premiums	Claim	Claim Adjustment	Percent	Expense Payments	Percent	Claims	Adjustment	Expense Incurred	Percent
Claims were Incurred	Earned	Payments	Expense Payments	(Col. 3/2)	(Col. 2 + 3)	(Col. 5/1)	Unpaid	Expenses	(Col. 5 + 7 + 8)	(Col. 9/1)
1. 2010	61,355	52,838	1,450	2.7	54,288	88.5	0	0	54,288	88.5
2. 2011	52,114	41,889	1,255	3.0	43,144	82.8	14	1	43,159	82.8
3. 2012	61,950	48,954	1,472	3.0	50,426	81.4	26	1	50,453	81.4
4. 2013	56,936	45,340	1,552	3.4	46,892	82.4	42	1	46,935	82.4
5. 2014	42,959	32,548	680	2.1	33,228		2,605	52	35,885	83.5

U & I Ex.-Pt.2C-Sn A-Paid Claims-Medicare Supp. NONE

U & I Ex.-Pt.2C-Sn B-Incurred Claims-Medicare Supp. NONE

U & I Ex.-Pt.2C-Sn C-Expense Ratio-Medicare Supp. NONE

U & I Ex.-Pt.2C-Sn A-Paid Claims-Dental NONE

U & I Ex.-Pt.2C-Sn B-Incurred Claims-Dental NONE

U & I Ex.-Pt.2C-Sn C-Expense Ratio-Dental NONE

U & I Ex.-Pt.2C-Sn A-Paid Claims-Vision NONE

U & I Ex.-Pt.2C-Sn B-Incurred Claims-Vision NONE

U & I Ex.-Pt.2C-Sn C-Expense Ratio-Vision NONE

U & I Ex.-Pt.2C-Sn A-Paid Claims-Fed Emp Health NONE

U & I Ex.-Pt.2C-Sn B-Incurred Claims-Fed Emp Health NONE

U & I Ex.-Pt.2C-Sn C-Expense Ratio-Fed Emp Health NONE

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED CLAIMS

(000 Omitted)

SECTION A - PAID HEALTH CLAIMS - TITLE XVIII - MEDICARE

			Cumulative Net Amounts Paid		
Year in Which Losses	1	2	3	4	5
Were Incurred	2010	2011	2012	2013	2014
1. Prior	820	827	835	835	835
2. 2010	16,246	17,722	17,721	17,724	17,723
3. 2011	XXX	15,290	16,732	16,740	16,738
4. 2012	XXX	XXX	22,965	25,029	25,012
5. 2013	XXX	XXX	XXX	34,397	37,142
6. 2014	XXX	XXX	XXX	XXX	52,398

SECTION B - INCURRED HEALTH CLAIMS - TITLE XVIII - MEDICARE

Ī		Sum of Cumu	lative Net Amount Paid and Claim Liabili	ity, Claim Reserve and Medical Ince	ntive Pool and Bonuses Outstanding at End	l of Year
_	Year in Which Losses	1	2	3	4	5
12	Were Incurred	2010	2011	2012	2013	2014
×	1. Prior	849	835	840	835	835
<	2. 2010	17,703	17,837	17,732	17,732	17,723
	3. 2011	XXX	17,388	16,745	16,751	16,746
	4. 2012	XXX	XXX	25,186	25,142	25,028
	5. 2013	XXX	XXX	XXX	38,113	37,211
	6. 2014	XXX	XXX	XXX	XXX	57,225

SECTION C - INCURRED YEAR HEALTH CLAIM AND CLAIM ADJUSTMENT EXPENSE RATIO - TITLE XVIII - MEDICARE

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in Which					Adjustment			Unpaid Claim	Claims Adjustment	,
Premiums were Earned and	Premiums	Claim	Claim Adjustment	Percent	Expense Payments	Percent	Claims	Adjustment	Expense Incurred	Percent
Claims were Incurred	Earned	Payments	Expense Payments	(Col. 3/2)	(Col. 2 + 3)	(Col. 5/1)	Unpaid	Expenses	(Col. 5 + 7 + 8)	(Col. 9/1)
1. 2010	20,384	17,723	283	1.6	18,006	88.3	0	0	18,006	88.3
2. 2011	20,632	16,738	330	2.0	17,068	82.7	8	0	17,076	82.8
3. 2012	31,269	25,012	504	2.0	25,516	81.6	16	0	25,532	81.7
4. 2013	41,343	37,142	752	2.0	37,894	91.7	69	1	37,964	91.8
5. 2014	61.758	52,398	793	1.5	53.191	86.1	4.827	91	58,109	94.1

U & I Ex.-Pt.2C-Sn A-Paid Claims-Medicaid NONE

U & I Ex.-Pt.2C-Sn B-Incurred Claims-Medicaid NONE

U & I Ex.-Pt.2C-Sn C-Expense Ratio-Medicaid NONE

U & I Ex.-Pt.2C-Sn A-Paid Claims-Other NONE

U & I Ex.-Pt.2C-Sn B-Incurred Claims-Other NONE

U & I Ex.-Pt.2C-Sn C-Expense Ratio-Other NONE

	PARI ZU	- AGGREGATE R	ESERVE FOR ACCI	DENT AND HEAL	TH CONTRACTS	JNLT		1 0	0
	Total	Comprehensive (Hospital and Medical)	Medicare Supplement	4 Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	9 Other
Unearned premium reserves	9,283	9,283	0	0	0	0	0	0	
2. Additional policy reserves (a)	0	0	0	0	0	0	0	0	
Reserve for future contingent benefits		0	0	0	0	0	0	0	
Reserve for rate credits or experience rating refunds (including \$) for investment income	17,800	48	0	0	0	0	17,752	0	
5. Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	
6. Totals (gross)	27,083	9,331	0	0	0	0	17,752	0	
7. Reinsurance ceded		0	0 .	0	0	0	0	0	
8. Totals (net) (Page 3, Line 4)	27,083	9,331	0	0	0	0	17,752	0	
Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	
Reserve for future contingent benefits	26,940	26,940	0	0	0	0	0	0	
Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	
2. Totals (gross)	26,940	26,940	0	0	0	0	0	0	
3. Reinsurance ceded	0	0	0	0	0	0	0	0	
4. Totals (net) (Page 3, Line 7)	26,940	26,940	0	0	0	0	0	0	
			DETAILS OF WE	RITE-INS					
501		0	0	0	0	0	0	0	
502	0	0	0	0	0	0	0	0	
503	0	0	0	0	0	0	0	0	
598. Summary of remaining write-ins for Line 5 from overflow page		0	0 .	0	0	0	0	0	
599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0 .	0	0	0	0	0	
101	0	0	0	0	0	0	0	0	
100		•		•					

1198. Summary of remaining write-ins for Line 11 from overflow page.. 1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)..

⁽a) Includes \$......0 premium deficiency reserve.

PART 3 - ANALYSIS OF EXPENSES

		Claim Adjustm	nent Expenses	3	4	5
		Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of own building)	874,739	4,220	75,159	222	954,340
2.	Salaries, wages and other benefits	0	206,685	2,806,352	10,876	3,023,913
3.	Commissions (less \$0 ceded plus \$0 assumed)	0	0	3,307,456	0	3,307,456
4.	Legal fees and expenses	11,010	2,601	12,426	137	26,174
5.	Certifications and accreditation fees	0	0	0	0	0
6.	Auditing, actuarial and other consulting services	0	35,638	636,585	0	672,223
7.	Traveling expenses	0	5,572	99,243	293	105,108
8.	Marketing and advertising	0	0	190,910	0	190,910
9.	Postage, express and telephone	0	13,926	248,016	733	262,675
10.	Printing and office supplies	0	7,450	133,195	392	141,037
11.	Occupancy, depreciation and amortization	238,938	0	0	0	238,938
12.	Equipment	0	10,804	192,419	569	203,792
13.	Cost or depreciation of EDP equipment and software	0	27,095	483,999	0	511,094
	Outsourced services including EDP, claims, and other services			766,567	2,971	825,995
15.	Boards, bureaus and association fees					
16.	Insurance, except on real estate					
17.	Collection and bank service charges					
18.	Group service and administration fees					
19.	Reimbursements by uninsured plans					
20.	Reimbursements from fiscal intermediaries					
21.	Real estate expenses.			116,924		
	Real estate taxes		·	·		
	Taxes, licenses and fees:					
20.	23.1 State and local insurance taxes	0	0	122 884	0	122,884
	23.2 State premium taxes					
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes			20,413		
	23.5 Other (excluding federal income and real estate taxes)			2,168,869		
	Investment expenses not included elsewhere					
24.						
25.	Aggregate write-ins for expenses					
26.	Total expenses incurred (Lines 1 to 25)		443,682		17,504	
27.	Less expenses unpaid December 31, current year		40,957		0	
28.	Add expenses unpaid December 31, prior year			31,666		
29.	Amounts receivable relating to uninsured plans, prior year			104,308		
	Amounts receivable relating to uninsured plans, current year					
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30) DETAILS	OF WRITE-INS	<u> 458,515</u>	12,699,547	<u> 17,504</u>	14,331,371
2501.	Pharmacy Rebate Expense		0	272,522	0	272,522
	Miscellaneous Expense.			68,923		,
	Interest Expense		0	1,937		
	Summary of remaining write-ins for Line 25 from overflow page			·		,
	TOTALS (Lines 2501 thru 2503 plus 2598) (Line 25 above)					, , ,

⁽a) Includes management fees of \$.....11,139,146 to affiliates and \$.......0 to non-affiliates.

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) EXHIBIT OF NET INVESTMENT INCOME

	EXHIBIT OF NET INVESTMENT INC	<u>UIVII</u>	<u> </u>		
			1		2
			Collected		Earned
			During Year		ring Year
1.	U.S. government bonds		428,560		410,178
1.1	Bonds exempt from U.S. tax	` '	0		0
1.2	Other bonds (unaffiliated)	(-)	241,827		1 -
1.3	Bonds of affiliates	` '	0		0
2.1	Preferred stocks (unaffiliated)	٠,			0
2.11	Preferred stocks of affiliates	` '	0		0
2.2	Common stocks (unaffiliated)				
2.21	Common stocks of affiliates				
3.	Mortgage loans				
4.	Real estate	(d)	0		0
5.	Contract loans		0		0
6.	Cash, cash equivalents and short-term investments	(e)	5,411		5,411
7.	Derivative instruments	(f)	0		0
8.	Other invested assets		0		0
9.	Aggregate write-ins for investment income		6,651		6,651
10.	Total gross investment income		682,449		653,085
11.	Investment expenses			(g)	16,619
12.	Investment taxes, licenses and fees, excluding federal income taxes			(g)	885
13.	Interest expense			(h)	0
14.	Depreciation on real estate and other invested assets			(i)	0
15.	Aggregate write-ins for deductions from investment income				0
16.	Total deductions (Lines 11 through 15)				17,504
17.	Net investment income (Line 10 minus Line 16)				635,581
-	DETAILS OF WRITE-INS				
0901.	Intercompany Interest		6,506		6,506
	Miscellaneous Interest				
0903.			0		0
0998.	Summary of remaining write-ins for Line 9 from overflow page		0		0
	Totals (Lines 0901 thru 0903 plus 0998) (Line 9 above)				6,651
					0
1502.					0
1503.					0
	Summary of remaining write-ins for Line 15 from overflow page				
	Totals (Lines 1501 thru 1503 plus 1598) (Line 15 above)				
(a)	Includes \$92,429 accrual of discount less \$46,809 amortization of premium and less \$0 paid for accrued interest				-
(b)	Includes \$0 accrual of discount less \$0 amortization of premium and less \$0 paid for accrued dividends				
(c)	Includes \$0 accrual of discount less \$0 amortization of premium and less \$0 paid for accrued interest or				
(d)	Includes \$0 for company's occupancy of its own buildings; and excludes \$0 interest on encumbrances.	,			
(e)	Includes \$5,411 accrual of discount less \$0 amortization of premium and less \$0 paid for accrued interest of	n purch	ases.		
(f)	Includes \$0 accrual of discount less \$0 amortization of premium.	- 2.011			
(g)	Includes \$0 investment expenses and \$0 investment taxes, licenses and fees, excluding federal income taxes	. attribut	able to Segregated and	Separate Acco	ounts.
(h)	Includes \$0 interest on surplus notes and \$0 interest on capital notes.	,			· - · · - ·
('')	The state of the s				

EXHIBIT OF CAPITAL GAINS (LOSSES)

(i) Includes \$......0 depreciation on real estate and \$......0 depreciation on other invested assets.

	LAHDH	OI CAFIIA		.000_0,		
		1	2	3	4	5
		Realized				Change in
		Gain (Loss)	Other	Total Realized	Change in	Unrealized
		on Sales	Realized	Capital Gain (Loss)	Unrealized	Foreign Exchange
		or Maturity	Adjustments	(Columns 1 + 2)	Capital Gain (Loss)	Capital Gain (Loss)
1.	U.S. government bonds	121,402	0	121,402	0	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	5,384	0	5,384	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	63	0	63	0	0
7.	Derivative instruments		0	0	0	0
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)			126,849	0	0
<u> </u>		DETAILS OF		<u> </u>		
0901.		0	0	0	0	0
0902.		0	0	0	0	0
0903.		0	0	0	0	0
		0	0	0	0	0
	Totals (Lines 0901 thru 0903 plus 0998) (Line 9 above)			0	0	0
5555.	Totalo (Elito coo i tilla coo piac coo) (Elito o abovo)					

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) EXHIBIT OF NONADMITTED ASSETS

		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)		0	` '
2.	Stocks (Schedule D):			
	2.1 Preferred stocks		0	0
	2.2 Common stocks	0	0	0
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens		0	0
	3.2 Other than first liens		0	0
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company	0	0	0
	4.2 Properties held for the production of income			
	4.3 Properties held for sale			
5.	Cash (Schedule E-Part 1), cash equivalents (Schedule E-Part 2)			
	and short-term investments (Schedule DA)	0	0	0
6.	Contract loans		0	0
7.	Derivatives (Schedule DB)	0	0	0
8.	Other invested assets (Schedule BA)		0	0
9.	Receivables for securities		0	0
10.	Securities lending reinvested collateral assets (Schedule DL)		0	0
11.	Aggregate write-ins for invested assets	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13.	Title plants (for Title insurers only)	0	0	0
14.	Investment income due and accrued	0	0	0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	83,728	99,300	15,572
	15.2 Deferred premiums, agents' balances and installments booked but			
	deferred and not yet due	0	0	0
	15.3 Accrued retrospective premiums		0	0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers	0	0	0
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts	0	0	0
17.	Amounts receivable relating to uninsured plans			
18.1	Current federal and foreign income tax recoverable and interest thereon	0	0	0
18.2	Net deferred tax asset	52,984	106,088	53,104
19.	Guaranty funds receivable or on deposit	0	0	0
20.	Electronic data processing equipment and software		0	0
21.	Furniture and equipment, including health care delivery assets	0	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates			
23.	Receivables from parent, subsidiaries and affiliates		0	0
24.	Health care and other amounts receivable	0	0	0
25.	Aggregate write-ins for other than invested assets	0	37,000	37,000
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected			
	Cell Accounts (Lines 12 through 25)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	TOTALS (Lines 26 and 27)	136,712	242,388	105,676
	DETAILS O	F WRITE-INS		
1101		0	0	0
1102		0	0	0
1103		0	0	0
1198	. Summary of remaining write-ins for Line 11 from overflow page	0	0	0
	. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)			
	Unbilled Claim Overpayment Recovery			
2502				
2503				
	. Summary of remaining write-ins for Line 25 from overflow page			
	. Totals (Lines 2501 thru 2503 plus 2598) (Line 25 above)			

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

	Total Members at End of					6			
	1	2	3	4	5	Current Year			
	Prior	First	Second	Third	Current	Member			
Source of Enrollment	Year	Quarter	Quarter	Quarter	Year	Months			
Health maintenance organizations	18,635	18,279	17,214	15,938	12,181	200,596			
Provider service organizations	0	0	0	0	0	0			
Preferred provider organizations	0	0	0	0	0	0			
4. Point of service	667	481	432	419	401	5,212			
5. Indemnity only	0	0	0	0	0	0			
6. Aggregate write-ins for other lines of business	0	0	0	0	0	0			
7. Total	19,302	18,760	17,646	16,357	12,582	205,808			
	DETAILS OF WRITE-INS								

	DET/ILLO VI TITULE III.O						
0601.	0	0	0	0			
0602	0		0	0			
0603	0 0	0 0	0	0			
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0					
0699 Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0			

NOTES TO FINANCIAL STATEMENTS

1. Summary of significant accounting policies

A. <u>Accounting practices</u>

The accompanying statutory financial statements of Aetna Health Inc. (a Maine corporation) (the "Company"), indirectly a wholly-owned subsidiary of Aetna Inc. ("Aetna"), have been prepared in conformity with accounting practices prescribed or permitted by the Maine Department of Professional and Financial Regulation, Bureau of Insurance ("Maine Department") ("Maine Accounting Practices"). The Maine Department recognizes only statutory accounting practices prescribed or permitted by the State of Maine for determining and reporting the financial condition and results of operations of an insurance company, which include accounting practices and procedures adopted by the National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures Manual ("NAIC SAP").

A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Maine for the years ending December 31, 2014 and 2013 is as follows:

	State of Domicile	December 31, 2014	December 31, 2013
Net income (loss) (derived using Maine Accounting Practices)	ME	\$2,559,654	\$(1,365,571)
State of Maine Prescribed Practices: None State of Maine Permitted Practices:	ME	-	-
None	ME	-	
Net income (loss) (derived using NAIC SAP)	=	\$2,559,654	\$(1,365,571)
Capital and surplus (derived using Maine Accounting Practices)	ME	\$15,669,848	\$13,908,387
State of Maine Prescribed Practices: None State of Maine Permitted Practices:	ME	-	-
None	ME	-	-
Capital and surplus (derived using NAIC SAP)	=	\$15,669,848	\$13,908,387

B. Use of estimates in the preparation of the financial statements

The preparation of these financial statements in conformity with Maine Accounting Practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses. Actual results could differ from those estimates.

C. Accounting policies

The Company applies the following significant accounting policies:

(1) Cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments, consisting primarily of money market instruments and other debt issues with an original maturity of up to one year, are carried at amortized cost. Short-term investments consist primarily of investments purchased with an original maturity date of greater than three months but less than one year. Cash equivalents consist of highly liquid instruments, which mature within three months from the date of purchase. The carrying amount of cash, cash equivalents and short-term investments approximates fair value.

(2) Bonds

Bonds, which include special deposits, are carried at amortized cost except for those bonds with an NAIC designation of 3 through 6, which are carried at the lower of amortized cost or fair value. The amount carried at fair value is not material to the financial statements. Bond premiums and discounts are amortized using the scientific interest method. When quoted prices in active markets for identical assets are available, the Company uses these quoted market prices to determine the fair value of bonds. This is used primarily for U.S. government securities. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, the Company estimates fair values using valuation methodologies based on available and observable market information or by using a matrix

pricing model. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. The Company had no investments where fair value was determined using broker quotes or an internal analysis of financial performance and cash flow projections at December 31, 2014 and 2013. Bonds include all investments whose maturity is greater than one year when purchased.

The Company periodically reviews its bonds to determine whether a decline in fair value below the carrying value is other-than-temporary. For bonds, other than loan-backed and structured securities, an other-than-temporary impairment ("OTTI") shall be recorded if it is probable that the Company will be unable to collect all amounts due according to the contractual terms in effect at the date of acquisition. Declines deemed to be OTTI in the cost basis are recognized as realized capital losses. Yield-related impairments are deemed other-than-temporary when the Company intends to sell an investment at the reporting date before recovery of the cost of the investment.

For loan-backed and structured securities, the Company records OTTI when the fair value of the loan-backed or structured security is less than the amortized cost basis at the balance sheet date and (1) the Company intends to sell the investment, or (2) the Company does not have the intent and ability to retain the investment for the time sufficient to recover the amortized cost basis, or (3) the Company does not expect to recover the entire amortized cost basis of the security, even if it does not intend to sell the security and has the intent and ability to hold. If it is determined an OTTI has occurred because of (1) or (2), the amount of the OTTI is equal to the difference between the amortized cost and the fair value of the security at the balance sheet date and this difference is recorded as a realized capital loss. If it is determined an OTTI has occurred because of (3), the amount of the OTTI is equal to the difference between the amortized cost and the present value of cash flows expected to be collected, discounted at the loan-backed or structured security's effective interest rate and this difference is also accounted for as a realized capital loss.

The Company analyzes all relevant facts and circumstances for each investment when performing its analysis to determine whether an OTTI exists. Among the factors considered in evaluating whether a decline is other-than-temporary, management considers whether the decline in fair value results from a change in the quality of the investment security itself, whether the decline results from a downward movement in the market as a whole, the prospects for realizing the carrying value of the bond based on the investee's current and short-term prospects for recovery and other factors. The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from our expectations and the risk that facts and circumstances factored into our assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods may result in a current period decision to sell securities that were not other-than-temporarily-impaired in prior reporting periods.

- (3) The Company did not own any common stock at December 31, 2014 or 2013.
- (4) The Company did not own any preferred stock at December 31, 2014 or 2013.
- (5) The Company did not have any mortgage loans at December 31, 2014 or 2013.
- (6) Securities lending

The Company engages in securities lending by lending certain securities from its investment portfolio to other institutions for short periods of time. Borrowers must post cash collateral in the amount of 102% to 105% of the fair value of a loaned security. The fair value of the loaned securities is monitored on a daily basis, with additional collateral obtained or refunded as the fair value of the loaned securities fluctuates. The collateral is retained and invested by a lending agent according to the Company's guidelines to generate additional investment income for the Company. Pursuant to Statements of Statutory Accounting Principles ("SSAP") No. 103 - Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities ("SSAP No. 103"), collateral required under the Company's securities lending program is carried on the Company's balance sheet as both a receivable and payable. Also pursuant to SSAP No. 103, if the collateral received from a counterparty is less than 100 percent at the reporting date, the difference between the actual collateral and 100 percent is nonadmitted. Collateral value is measured and compared to the loaned securities in aggregate by counterparty. The Company did not have any loaned securities at December 31, 2014 or 2013.

- (7) The Company did not have any investments in any subsidiaries or affiliated companies at December 31, 2014 or 2013.
- (8) The Company did not have any investments in any joint ventures, partnerships and limited liability companies at December 31, 2014 or 2013.
- (9) The Company did not have any derivatives at December 31, 2014 or 2013.

(10) Aggregate health policy reserves and related expenses

The Company offers individual conversion policies to individuals that were previously covered by a qualifying group policy. These policies are generally renewable at the option of the policyholder and statutory regulations preclude the Company from canceling coverages and may limit premium rate increases. Due to Federal Health Care Reform, the vast majority of these policies terminated in 2014. The Company has established an individual conversion reserve ("ICR") for such policies. The ICR represents the estimated net present value of future benefits to be paid to or on behalf of policyholders and related expenses less the estimated present value of future net premiums. The Company estimates its ICR using actuarial principles and assumptions which consider, among other things, contractual requirements, future premium increases, discount rates, historical utilization trends and payment patterns, persistency of membership and other relevant factors based on the Company's experience. ICR expenses are recorded as an increase in reserves for life and accident and health contracts. The Company had no ICR at December 31, 2014 or 2013.

Premium deficiency reserves ("PDR") are recognized when it is probable that the expected future hospital and medical costs, including maintenance costs, will exceed anticipated future premiums and reinsurance recoveries on existing contracts. Where allowed, anticipated investment income is considered in the calculation of any PDR. For purposes of calculating a PDR, contracts are grouped in manner consistent with the method of acquiring, servicing and measuring the profitability of such contracts. The Company had no PDR at December 31, 2014. The PDR balance of \$2,119,593 was included in aggregate health policy reserves in the Statutory Statement of Liabilities, Capital and Surplus at December 31, 2013.

Unearned premium reserves ("UEP") are recognized for premiums that are recorded by the Company that have not been earned as of the statement date. The UEP balances of \$9,283 and \$30,945 were included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus at December 31, 2014 and 2013, respectively.

The Company is required to make premium rebate payments to customers that are enrolled under certain health insurance policies if specific minimum annual medical loss ratios ("MLR") are not met in the prior year. The Company's results for full-years 2014 and 2013 included an estimate of \$48 and \$405, respectively, of minimum MLR rebates, which were included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus.

(11) Hospital and medical costs and claims adjustment expenses and related reserves

Hospital and medical costs consist principally of fee-for-service medical claims and capitation costs. Claims unpaid include the Company's estimate of payments to be made on claims reported but not yet paid and for health care services rendered to enrollees but not yet reported to the Company as of the Statutory Statements of Assets and Liabilities, Capital and Surplus date. Such estimates are developed using actuarial principles and assumptions, which consider, among other things, historical and projected claim submission and processing patterns, medical cost trends, historical utilization of health care services, claim inventory levels, changes in membership and product mix, seasonality and other relevant factors. The Company reflects changes in estimates in hospital and medical costs in the Statutory Statements of Revenue and Expenses in the period they are determined. Capitation costs, which are recorded in hospital and medical expenses in the Statutory Statements of Revenue and Expenses, represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the medical services provided to the enrollee.

The Company uses the triangulation method to estimate reserves for claims incurred but not reported. The method of triangulation makes estimates of completion factors that are then applied to the total paid claims (net of coordination of benefits) to date for each incurral month. This provides an estimate of the total projected incurred claims and total amount outstanding or claims incurred but not reported (claims unpaid). For the most current dates of service where there is insufficient paid claim data to rely solely on the triangulation method, the Company examines cost and utilization trends as well as environmental factors, plan changes, provider contracts, changes in membership and/or benefits, and historical seasonal patterns to estimate the reserve required for these months.

Claims adjustment expenses, which include cost containment expenses, represent the costs incurred related to the claim settlement process such as costs to record, process and adjust claims. These expenses are included in the Company's management agreement with an affiliate described in Note 10.

(12) The Company did not modify its capitalization policy from the prior period.

(13) Pharmaceutical rebate receivables

The Company estimates pharmaceutical rebate receivables based upon historical payment trends, actual utilization and other variables. Pharmaceutical rebates for a quarter are billed to the vendor within one month of the completion of the quarter with any adjustment to previously recorded amounts reflected at the time of billing. The Company reports pharmaceutical rebate receivables as health care receivables. Pharmacy rebate receivables over 90 days past due are nonadmitted. All rebates are processed and settled with an affiliated entity.

(14) Premiums and amounts due and unpaid

Premium revenue for prepaid health care products is recognized as income in the month in which enrollees are entitled to health care services. Premiums collected before the effective period are reported as premiums received in advance. Premiums related to unexpired contractual coverage periods are reported as unearned premiums in the Statutory Statements of Liabilities, Capital and Surplus (refer to discussion of aggregate health policy reserves and related expenses above).

Nonadmitted amounts consist of all premiums due and unpaid greater than 90 days past due, with the exception of amounts due under government insured plans, which may be admitted assets under certain circumstances. In addition, for any customer for which the premiums due and unpaid greater than 90 days past due is more than a de minimus portion of the entire balance of premiums due and unpaid for that customer, the entire balance of premiums due and unpaid for that customer is nonadmitted. Management also performs a specific review of accounts and based on the results of the review, additional amounts may be nonadmitted. Uncollectible amounts are generally written-off and charged to revenue in the period in which the customer reconciliations are completed and agreed to by the customer (retroactivity) or when the account is determined to be uncollectible by the Company.

(15) Aggregate health claim reserves

The reserve for future contingent benefits includes the estimated cost of services that will continue to be incurred after the Statutory Statements of Liabilities, Capital and Surplus date if the Company is obligated to pay for such services in accordance with contract provisions or regulatory requirements. These balances are recorded in aggregate health claim reserves in the Statutory Statements of Liabilities, Capital and Surplus and are estimated using a percentage of current hospital and medical costs, which is based on the Company's historical cost experience.

(16) Investment income due and accrued

Accrued investment income consists primarily of interest. Interest is recognized on an accrual basis and dividends are recorded as earned on the ex-dividend date. Due and accrued income is not recorded on: (a) bonds in default; and (b) bonds delinquent more than 90 days or where collection of interest is improbable. At December 31, 2014 and 2013, the Company did not have any nonadmitted investment income due and accrued.

(17) Covered and uncovered expenses and related liabilities

Covered expenses and related liabilities represent costs for health care expenses for which a member is not responsible in the event of the insolvency of the Company. Uncovered expenses and related liabilities represent costs to the Company for health care services that are the obligation of the Company and for which a member may also be liable in the event of the Company's insolvency.

(18) Health Insurer Fee

Effective January 1, 2014, SSAP No. 35 – Revised, *Guaranty Fund and Other Assessments* ("SSAP No. 35R") was revised to adopt Financial Accounting Standards Board Accounting Standards Update 2011-06, *Other Expenses – Fees Paid to the Federal Government by Health Insurers* ("ASU 2011-06") with modifications. ASU 2011-06 provides specific guidance related to the assessment of the annual fee ("health insurer fee") mandated to be paid to the federal government by health insurers under Section 9010 of the Affordable Care Act ("ACA"). In June 2014, the guidance in SSAP No. 35R related to the health insurer fee was moved from SSAP No. 35R to SSAP No. 106 – *Affordable Care Act Assessments* ("SSAP No. 106"). Beginning January 1, 2014, SSAP No. 106 required (1) that the health insurer fee be recognized in full on January 1 of the fee year (the calendar year in which the assessment must be paid to the federal government), in the operating expense category of insurance taxes, licenses and fees, excluding federal income taxes and (2) that in each data year preceding a fee year a reporting entity proratably accrue by reclassifying from unassigned funds (surplus) to aggregate write-ins for special surplus funds an amount equal to its estimated subsequent fee year assessment. This reclassification has no impact on total capital and surplus and is reversed in full on January 1 of the fee year beginning with fee years starting on January 1, 2015 and after. See Note 22 for disclosure of all amounts related to the health insurer fee for the Company.

(19) Accounting for the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010's (collectively, "Health Care Reform") Reinsurance, Risk Adjustment and Risk Corridor (the "3Rs") pursuant to SSAP No. 107 – Accounting for the Risk-Sharing Provisions of the Affordable Care Act ("SSAP No. 107")

Reinsurance

Health Care Reform established a temporary three-year reinsurance program, under which all issuers of major medical commercial insurance products and self-insured plan sponsors are required to contribute funding in amounts set by the U.S. Department of Health and Human Services ("HHS"). Funds collected will be utilized to reimburse issuers' high claims costs incurred for qualified individual members. The expense related to this required funding is reflected in insurance, taxes, licenses and fees for all of the

Company's insurance products with the exception of products associated with qualified individual members; this expense for qualified individual members is reflected as a reduction of premium revenue. When annual claim costs incurred by the Company's qualified individual members exceed a specified attachment point, the Company is entitled to certain reimbursements from this program. The Company records amounts recoverable for claims paid and unpaid and ceded claim benefit recoveries to reflect its estimate of these recoveries.

Risk Adjustment

Health Care Reform established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company's qualified plan members relative to the average risk of members of other qualified plans in comparable markets, the Company estimates its ultimate 2014 risk adjustment receivable or payable and reflects the impact as an adjustment to its premium revenue.

Risk Corridor

Health Care Reform established a temporary three-year risk sharing program for qualified individual and small group insurance plans. Under this program the Company makes (or receives) a payment to (or from) HHS based on the ratio of allowable costs to target costs (as defined by Health Care Reform). The Company records a risk corridor receivable or payable as an adjustment to premium revenue based on the Company's estimate of the ultimate 2014 risk sharing amount.

The Company will perform a final reconciliation and settlement with HHS of the 2014 3Rs during 2015. See Note 24.E. for disclosure of amounts related to the 3Rs for the Company for the period ending December 31, 2014.

(20) Federal and state income taxes

The Company is included in the consolidated federal income tax return of its parent company, Aetna and Aetna's other wholly-owned subsidiaries pursuant to the terms of a tax sharing agreement. In accordance with a written tax sharing agreement with an affiliate, the Company's current federal and state income tax provisions are generally computed as if the Company were filing a separate federal and state income tax return; current income tax benefits, including those resulting from net operating losses, are recognized to the extent realized in the consolidated return. Pursuant to this agreement, the Company has the enforceable right to recoup federal and state income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal and state income taxes.

Income taxes are accounted for under the asset and liability method. Deferred income tax assets ("DTAs") and liabilities ("DTLs") represent the expected future tax consequences of temporary differences generated by statutory accounting as defined in SSAP No. 101, Income Taxes – A Replacement of SSAP No. 10R and SSAP No. 10 ("SSAP No. 101"). DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. DTAs and DTLs are computed by means of identifying temporary differences which are measured using a balance sheet approach whereby statutory and tax basis balance sheets are compared. Current income tax recoverables include all current income taxes, including interest, reasonably expected to be recovered in a subsequent accounting period.

Pursuant to SSAP No. 101, gross DTAs are first reduced by a statutory valuation allowance adjustment to an amount that is more likely than not to be realized ("adjusted gross DTAs"). Adjusted gross DTAs are then admitted in an amount equal to the sum of paragraphs a. b. and c. below:

- Federal income taxes paid in prior years that can be recovered through loss carrybacks for existing temporary differences that reverse during a timeframe corresponding with Internal Revenue Service ("IRS") tax loss carryback provisions.
- b. The amount of adjusted gross DTAs, after the application of paragraph a. above, expected to be realized within the applicable period and that is no greater than the applicable percentage as determined using the applicable Realization Threshold Limitation Table. The applicable period refers to the number of years in which the DTA will reverse in the Company's tax return and the applicable percentage refers to the percentage of the Company's statutory capital and surplus as required to be shown on the statutory balance sheet adjusted to exclude any net DTAs, electronic data processing equipment and operating system software and any net positive goodwill ("Stat Cap ExDTA").

The Realization Threshold Limitation Tables allow DTAs to be admitted based upon either realization within 3 years and 15% percent of Stat Cap ExDTA, 1 year and 10% of Stat Cap ExDTA, or no DTA admitted pursuant to this paragraph b. In general, the Realization Threshold Limitation Tables allow the Company to admit more DTAs if total DTAs as reported by the Company are a smaller percentage of statutory capital and surplus.

c. The amount of gross DTAs, after the application of paragraphs a. and b. above that can be offset against existing gross DTLs. In applying this offset, the Company considers the character (i.e. ordinary versus capital) of the DTAs and DTLs such that offsetting would be permitted in the tax return under existing enacted federal income tax laws and regulations and the reversal patterns of temporary differences.

Changes in DTAs and DTLs are recognized as a separate component of gains and losses in surplus ("Change in net deferred income tax") except to the extent allocated to changes in unrealized gains and losses. Changes in DTAs and DTLs allocated to unrealized gains and losses are netted against the related changes in unrealized gains and losses and are reported as "Change in net unrealized capital gains (losses)", also a separate component of gains and losses in surplus.

State income tax expense is recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses. For the years ended December 31, 2014 and 2013, the Company incurred state income tax expense (recoveries) of \$122,884 and \$(12,760), respectively. At December 31, 2014 and 2013, the Company reported \$146,417 and \$165,220, respectively, as state income tax receivable, which was included as write-ins in the Statutory Statements of Assets.

(21) Reinsurance

In the normal course of business, the Company seeks to reduce the loss that may arise from catastrophes or other events that cause unfavorable underwriting results and to help balance its risks and capital by reinsuring certain levels of risk with other insurance enterprises. Reinsurance premiums and reserves related to reinsured business are accounted for on a basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts. Premiums ceded for medical losses and the related unpaid reserves have been reported as reductions of these items. The reinsurance agreement is more fully discussed in Note 23.

2. Accounting changes and corrections of errors

During 2014, the Company recorded a correction to prescription drugs, for prior year dates of service, in the amount of \$50,033 to properly reflect the payments associated with pharmacy claims. This adjustment and its tax effect were included as write-ins in the Statutory Statements of Revenue and Expenses (Continued).

The Company did not have any accounting changes in the year ended December 31, 2014. The Company did not have any accounting changes or corrections of errors in the year ended December 31, 2013.

3. Business combinations and goodwill

The Company was not a part of any business combinations that involved the statutory purchase method, a statutory merger, an assumption reinsurance, or an impairment loss in the years ending December 31, 2014 and 2013.

4. Discontinued operations

The Company did not have any discontinued operations in the years ending December 31, 2014 and 2013.

5. Investments

- A. The Company did not have any mortgage loans, including Mezzanine Real Estate Loans, at December 31, 2014 or 2013.
- B. The Company did not have any debt restructuring in the years ending December 31, 2014 and 2013.
- C. The Company did not have any reverse mortgages at December 31, 2014 or 2013.

D. Loan-Backed Securities

- (1) Prepayment assumptions for single class and multi-class mortgage backed/asset backed securities were obtained from industry market sources.
- (2) The Company had no OTTI losses during 2014 on loan-backed and structured securities in which the Company had the (1) intent to sell, (2) did not have the intent and ability to retain for a period of time sufficient to recover the amortized cost basis or (3) present value of cash flows expected to be collected is less than the amortized cost basis of the securities in accordance with SSAP No. 43R, *Loan-Backed and Structured Securities*.
- (3) The Company had no recognized OTTI on loan-backed and structured securities currently held, in which the present value of cash flows expected to be collected is less than the amortized cost basis, at December 31, 2014.
- (4) The Company had no unrealized loss position on loan-backed and structured securities held by the Company at December 31, 2014.

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation)

E. Repurchase Agreements and/or Securities Lending Transactions

- (1) The Company did not have any repurchase agreements or loaned securities transactions at December 31, 2014.
- (2) The Company did not pledge any of its assets as collateral, which are classified as securities pledged to creditors as of December 31, 2014.
- (3) Neither the Company nor its agent has accepted collateral that is permitted by contract or custom to sell or repledge as of December 31, 2014.
- (4) The Company did not have securities lending transactions administered by an affiliated agent which is "one line" reported at December 31, 2014.
- (5) The Company did not have any repurchase agreements, loaned securities or dollar repurchase agreements at December 31, 2014.
- (6) The Company has not accepted collateral that is not permitted by contract or custom to sell or repledge as of December 31, 2014.
- (7) The Company did not have any collateral for transactions that extend beyond one year from the reporting date.
- F. The Company did not have any real estate at December 31, 2014 or 2013.
- G. The Company did not have any low-income housing tax credits at December 31, 2014.

H. Restricted Assets

(1) Restricted assets (including pledged):

Restricted Asset Current from cyear of the contractual of the contractual of the cyear of the cy		1	2	3	4	5	6
Restricted Asset Category as Increase Restricted from current year gross restricted from category year year year with prior year (1 minus 2) restricted admitted admitted assets assets of the contractual obligation for which liability is not shown b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to toollar reverse repurchase agreements as a subject to dollar reverse repurchase agreements c. Subject to dollar reverse repurchase agreement c. Subject to dollar reverse repur		·		3	4	5	
Restricted Aset from current year gross restricted from current year (decrease) (admitted restricted assets to total admitted assets to total admitted restricted asset to total admitted restricted asset to total assets to total admitted restricted asset to total asset to total asset to total admitted restricted asset to total admitted rest			T-4-1		T-4-1	D	
Restricted Asset current current clategory as a collateral to collate assets assets as a collateral to collate assets as collateral to collate assets as collateral to col						_	
Restricted Asset Vear year prior year (1 minus 2) admitted restricted assets 3. Subject to contractual obligation for which liability is not shown b. Collateral held under security lending agreements c. Subject to repurchase agreements c. Subject to obliar repurchase agreements e. Subject to dollar repurchase agreements e. Subject to dollar repurchase agreements for the termination of the termination o							
Category year prior year (1 minus 2) restricted assets assets a. Subject to contractual obligation for which liability is not shown b. Collatoral held under security lending agreements c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to ollar reverse repurchase agreements h. Subject to ollar reverse agreements h. Subject to ollar restricted so so securities restricted as so sale excluding PHLB capital stock i. FHLB capital stock i. FHLB capital stock i. Ondeposit with other regulatory bodies i. Pleaged as collateral for HLB (including assets backing funding agreements) ii. Pleaged as collateral for hHLB (including assets backing funding agreements) iii. Pleaged as collateral for capitured in other categories iii. Pleaged as collateral for capitured in other categories iii. Pleaged as collateral for capitured in other categories iii. Pleaged as collateral for capitured in other categories iii. Pleaged as collateral for capitured in other categories iii. Pleaged as collateral for capitured in other categories iii. Onter restricted assets iii. Onter restricted assets iii. Onter restricted iii. In other categories iii. Onter restricted assets iii. Onter restricted		_			,		
a. Subject to contractual obligation for which flability is not shown b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar reverse repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale excluding FHLB capital stock i. FHLB capital stock j. On deposit with states stock l. On deposit with other regulatory bodies h. On deposit with other regulatory bodies h. Pledged as collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral to FHLB (including agreements) n. Other restricted assets o. Total restricted	Restricted Asset	current	_			to total	admitted
contractual obligation for which liability is not shown b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar repurchase agreements greements greements h. Letter stock or securities restricted as to sale	Category	year	prior year	(1 minus 2)	restricted	assets	assets
obligation for which liability is not shown b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to dollar repurchase agreements e. Subject to dollar repurchase agreements for workse agreements greenwents e. Subject to dollar repurchase agreements for workse repurchase agreements green repurchase agreements for workse repurchase agreements for workse repurchase agreements for workse repurchase agreements green repurchase agreements green repurchase agreements for workse repurchase ag	a. Subject to						
which liability is not shown b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements e. Subject to dollar repurchase agreements greements e. Subject to dollar repurchase agreements f. Subject to dollar repurchase agreements greements e. Subject to dollar repurchase agreements f. Subject to dollar repurchase agreements greements f. Subject to dollar repurchase agreements greements greements f. Subject to dollar repurchase agreements greements	contractual						
which liability is not shown b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements e. Subject to dollar repurchase agreements greements e. Subject to dollar repurchase agreements f. Subject to dollar repurchase agreements greements e. Subject to dollar repurchase agreements f. Subject to dollar repurchase agreements greements f. Subject to dollar repurchase agreements greements greements f. Subject to dollar repurchase agreements greements	obligation for						
not shown							
b. Collateral held under security lending agreements		_	-	_	_	_	_
under security lending agreements C. Subject to repurchase agreements Output to to reverse repurchase agreements Subject to dollar repurchase agreements Subject to dollar repurchase agreements Publication of the subject to dollar repurchase agreements Subject to dollar repurchase agreements Publication of the subject to description of the subject to dollar repurchase agreements Publication of the subject to dollar repurchase agreements Publication of the subject to description of the subject to dollar repurchase agreements Publication of the subject to dollar repurchase agreements Publica							
lending agreements C. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock k. On deposit with other regulatory bodies k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets 1. On the restricted assets 1. On the restricted assets 2. On tarrestricted 3. On tarrestricted 4. On deposit with other regulatory bodies 5. On tarrestricted 6. On tarrestricted							
agreements C. Subject to repurchase agreements d. Subject to treverse repurchase agreements e. Subject to dollar repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase							
C. Subject to repurchase agreements	_						
repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar repurchase agreements greements f. Subject to dollar repurchase agreements greements g		-	-	-	-	-	-
agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale excluding FHLB capital stock i. FHLB capital stock i. FHLB capital stock i. PHLB capital stock ii. PHLB capital stock ii. PHLB capital stock ii. PHLB capital stock iii. PHLB capita							
d. Subject to reverse repurchase agreements							
reverse repurchase agreements		-	-	-	-	-	-
repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock f. FHLB capital stock h. Do deposit with states k. On deposit with other regulatory bodies funding agreements gareements							
agreements - Subject to dollar repurchase agreements - Subject to dollar reverse repurchase repurchase agreements							
e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including agreements) m. Pledged as collateral not captured in other categories n. Other restricted as capital stock l. Pledged as collateral not captured in other categories n. Other restricted as capital stock l.	repurchase						
e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including agreements) m. Pledged as collateral not captured in other categories n. Other restricted as capital stock l. Pledged as collateral not captured in other categories n. Other restricted as capital stock l.		-	-	-	-	-	-
repurchase agreements f. Subject to dollar reverse repurchase agreements							
agreements - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -							
f. Subject to dollar reverse repurchase agreements		_	_	_	_	_	_
reverse repurchase agreements							
repurchase agreements							
g. Placed under option contracts							
g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states k. On deposit with other regulatory bodies collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets n. Other restricted							
Option contracts		-	-	-	-	-	-
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock							
securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states st		-	-	-	-	-	-
restricted as to sale - excluding FHLB capital stock							
as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states \$403,334 \$403,894 \$(560) \$403,334 \$1.438% \$1.445% k. On deposit with other regulatory bodies I. Pledged as collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets							
excluding FHLB capital stock							
Capital stock							
i. FHLB capital stock							
Stock - - - - - - - -		-	-	-	-	-	-
Stock - - - - - - - -	i. FHLB capital						
j. On deposit with states \$403,334 \$403,894 \$(560) \$403,334 \$1.438% \$1.445% k. On deposit with other regulatory bodies		-	-	-	-	-	-
states \$403,334 \$403,894 \$(560) \$403,334 1.438% 1.445% k. On deposit with other regulatory bodies - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
k. On deposit with other regulatory bodies		\$403.334	\$403.894	\$(560)	\$403.334	1,438%	1.445%
other regulatory bodies		Ţ : ; 	+ ,	+(-00)	Ţ : 2 3,0 0 ·	1113070	11110,0
regulatory bodies I. Pledged as collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets o. Total restricted							
bodies							
I. Pledged as collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets o. Total restricted							
collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets o. Total restricted		-	-	-	-	-	-
FHLB (including assets backing funding agreements)							
assets backing funding agreements)							
funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets o. Total restricted							
agreements) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
m. Pledged as collateral not captured in other categories n. Other restricted assets o. Total restricted	tunding						
collateral not captured in other categories	agreements)	-	-	-	-	-	-
captured in other categories	m. Pledged as						
captured in other categories							
other categories - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -							
n. Other restricted assets		-	-	-	-	-	-
assets							
o. Total restricted		_	_	_	_	_	_
<u> </u>		\$403 334	\$403.804	\$(560)	\$403.334	1 //38%	1 //5%
	assets	ψ+υυ,υυ4	ψ+υυ,υϋ4	ψ(300)	ψ 4 03,33 4	1.430 /0	1. 14 0/0

- (2) The Company did not have any assets pledged as collateral not captured in other categories at December 31, 2014.
- (3) The Company did not have any other restricted assets at December 31, 2014.
- I. The Company did not have any working capital finance investments at December 31, 2014.
- J. The Company did not have any offsetting and netting of financial assets as of December 31, 2014.
- K. The Company did not have any structured notes at December 31, 2014.

6. <u>Joint ventures, partnerships, and limited liability companies</u>

- A. The Company did not have any joint ventures, partnerships, or limited liability companies that exceeded 10% of its admitted assets at December 31, 2014 or 2013.
- B. The Company does not have any impaired investments in joint ventures, partnerships, or limited liability companies at December 31, 2014 or 2013.

7. Investment income

A. and B.

There was no investment income due and accrued excluded from surplus at December 31, 2014 or 2013.

8. Derivative instruments

The Company did not have any derivative instruments at December 31, 2014 or 2013.

9. Income taxes

A.

1. The components of the net DTAs recognized in the Company's Statutory Statements of Assets, Liabilities, Surplus and Other Funds are as follows:

	D	ecember 31, 201	4
	Ordinary	Capital	Total
(a) Gross DTAs	\$60,838	\$295,106	\$355,944
(b) Statutory valuation allowance adjustment		(28,036)	(28,036)
(c) Adjusted gross DTAs	60,838	267,070	327,908
(d) DTAs nonadmitted		(52,984)	(52,984)
(e) Subtotal net admitted DTAs	60,838	214,086	274,924
(f) DTLs	(109,123)	(63,998)	(173,121)
(g) Net admitted DTAs/(DTLs)	\$(48,285)	\$150,088	\$101,803
	D	ecember 31, 201	3
	Ordinary	Capital	Total
(a) Gross DTAs	\$835,001	\$295,106	\$1,130,107
(b) Statutory valuation allowance adjustment(c) Adjusted gross DTAs	835,001	(6,687) 288,419	(6,687) 1,123,420
(d) DTAs nonadmitted	035,001	(106,088)	(106,088)
(e) Subtotal net admitted DTAs	835,001	182,331	1,017,332
(f) DTLs	-	(32,243)	(32,243)
(g) Net admitted DTAs/(DTLs)	\$835,001	\$150,088	\$985,089
()		. ,	. ,
		Change	
	Ordinary	Capital	Total
(a) Gross DTAs	\$(774,163)	_	\$(774,163)
(b) Statutory valuation allowance adjustment	-	\$(21,349)	(21,349)
(c) Adjusted gross DTAs	(774,163)	(21,349)	(795,512)
(d) DTAs nonadmitted	<u> </u>	53,104	53,104
(e) Subtotal net admitted DTAs	(774,163)	31,755	(742,408)
(f) DTLs	(109,123)	(31,755)	(140,878)
(g) Net admitted DTAs/(DTLs)	\$(883,286)	-	\$(883,286)

2. The amount of admitted gross DTAs admitted under each component of SSAP No. 101:

	D	ecember 31, 20	14
	Ordinary	Capital	Total
(a) Federal income taxes paid in prior years recoverable through loss carrybacks(b) Adjusted gross DTAs expected to be realized	-	\$66,847	\$66,847
(excluding the amount of DTAs) after application of the threshold limitations (the lesser of 2(b)1 and 2(b)2 below) 1. Adjusted gross DTAs expected to realized	\$60,838	83,241	144,079
following the balance sheet date	60,838	83,241	144,079
Adjusted gross DTAs allowed per limitation threshold	XXX	XXX	2,335,207
(c) Adjusted gross DTAs (excluding the amount of DTAs from 2(a) and 2(b) above) offset by gross DTLs	_	63,998	63,998
(d) DTAs admitted as the result of application of SSAP No. 101	\$60,838	\$214,086	\$274,924
		ecember 31, 20	13
	Ordinary	Capital	Total
 (a) Federal income taxes paid in prior years recoverable through loss carrybacks (b) Adjusted gross DTAs expected to be realized (excluding the amount of DTAs) after application 	\$835,001	-	\$835,001
of the threshold limitations (the lesser of 2(b)1 and 2(b)2 below) 1. Adjusted gross DTAs expected to realized	-	\$150,088	150,088
following the balance sheet date	-	150,088	150,088
Adjusted gross DTAs allowed per limitation threshold	XXX	XXX	1,938,495
(c) Adjusted gross DTAs (excluding the amount of DTAs from 2(a) and 2(b) above) offset by gross DTLs		32,243	32,243
(d) DTAs admitted as the result of application of SSAP No. 101	\$835,001	\$182,331	\$1,017,332
		Change	
	Ordinary	Capital	Total
 (a) Federal income taxes paid in prior years recoverable through loss carrybacks (b) Adjusted gross DTAs expected to be realized (excluding the amount of DTAs) after application of the throughold limitations (the losses of 2/b) 1 	\$(835,001)	\$66,847	\$(768,154)
of the threshold limitations (the lesser of 2(b)1 and 2(b)2 below)	60,838	(66,847)	(6,009)
Adjusted gross DTAs expected to realized following the balance sheet date Adjusted gross DTAs expected to realized attentions and the state of	60,838	(66,847)	(6,009)
 Adjusted gross DTAs allowed per limitation threshold 	XXX	XXX	396,712
(c) Adjusted gross DTAs (excluding the amount of DTAs from 2(a) and 2(b) above) offset			
by gross DTLs (d) DTAs admitted as the result of application of	-	31,755	31,755
SSAP No. 101	\$(774,163)	\$31,755	\$(742,408)
	2014	2	013
 (a) Ratio percentage used to determine recovery period and threshold limitation amount (b) Amount of adjusted capital and surplus used to determine recovery period threshold limitation 	384%	3	40%
determine recovery period threshold limitation in 2(b)2 above	\$15,568,0	45 \$12,9	923,298

3.

4. The impact of tax planning strategies is as follows:

		December 31, 20	14
	Ordinary	Capital	Total
 (a) Determination of adjusted gross DTAs and net admitted DTAs, by tax character as a percentage 1. Adjusted gross DTAs amount from Note 9A1(c) 2. Percentage of adjusted DTAs by tax 	\$60,838	\$267,070	\$327,908
character attributable to the impact of tax planning strategies	0%	81%	81%
 3. Net admitted adjusted gross DTAs amount from Note 9A1(e) 4. Percentage of net admitted adjusted DTAs by tax character admitted 	\$60,838	\$214,086	\$274,924
because of the impact of tax planning strategies	0%	78%	78%
		December 31, 20	13
	Ordinary	Capital	Total
 (a) Determination of adjusted gross DTAs and net admitted DTAs, by tax character as a percentage 1. Adjusted gross DTAs amount from Note 9A1(c) 2. Percentage of adjusted DTAs by tax 	\$835,001	\$288,419	\$1,123,420
character attributable to the impact of tax planning strategies	0%	26%	26%
 3. Net admitted adjusted gross DTAs amount from Note 9A1(e) 4. Percentage of net admitted adjusted DTAs by tax character admitted because of the impact of tax 	\$835,001	\$182,331	\$1,017,332
planning strategies	0%	18%	18%
		Change	
	Ordinary	Capital	Total
 (a) Determination of adjusted gross DTAs and net admitted DTAs, by tax character as a percentage 1. Adjusted gross DTAs amount from Note 9A1(c) 2. Percentage of adjusted DTAs by tax character attributable to the impact 	\$(774,163)	\$(21,349)	\$(795,512)
of tax planning strategies	0%	55%	55%
 3. Net admitted adjusted gross DTAs amount from Note 9A1(e) 4. Percentage of net admitted adjusted DTAs by tax character admitted because of the impact of tax 	\$(774,163)	\$31,755	\$(742,408)
planning strategies	0%	60%	60%
(1) 5 (1 0 1 1 1 1 1 1 1 1 1		0.14	NI V

- (b) Does the Company's tax-planning strategies include the use of reinsurance? Yes $\underline{\hspace{1cm}}$ No $\underline{\hspace{1cm}}$ X
- B. There are no DTLs that were not recognized at December 31, 2014 or 2013.
- C. Current income taxes incurred consist of the following major components:

		Decer		
		2014	2013	Change
1.	Current income tax			
	(a) Federal	\$256,566	\$(425,705)	\$682,271
	(b) Foreign	-	-	-
	(c) Subtotal	256,566	(425,705)	682,271
	(d) Federal income tax on net capital gains	44,397	5,945	38,452
	(f) Other	-	-	-
	(g) Federal and foreign income taxes incurred	\$300,963	\$(419,760)	\$720,723

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation)

		Decem	_	
		2014	2013	Change
0	DTA -			
2.	DTAs:			
(a)	Ordinary Claims unpaid	\$24,066	\$35,136	\$(11,070)
	Uncollected premiums - nonadmitted	2,565	2,166	399
	Premium deficiency reserve	-	741,858	(741,858)
	CMS Risk Share	-	4,939	(4,939)
	Long-term prepaid expenses - nonadmitted Patient-Centered Outcomes Research	-	12,950	(12,950)
	Institute fee	4,902	3,197	1,705
	Premiums receivable - nonadmitted	29,305	34,755	(5,450)
	Total ordinary DTAs	60,838	835,001	(774,163)
	Statutory valuation allowance adjustment	-	-	-
(c)	Nonadmitted ordinary DTAs	-	-	-
(d)	Admitted ordinary DTAs	60,838	835,001	(774,163)
(e)	Capital			
(-)	Investments	295,106	295,106	-
	Total capital DTAs	295,106	295,106	-
(f)	Statutory valuation allowance adjustment	(28,036)	(6,687)	(21,349)
(g)	Nonadmitted capital DTAs	(52,984)	(106,088)	53,105
(h)	Admitted capital DTAs	214,086	182,331	31,756
(i)	Admitted DTAs	274,924	1,017,332	(742,408)
3. (a)	DTLs: Ordinary			
	Allowance for billing adjustment	109,123	-	109,123
	Ordinary DTLs	109,123	-	109,123
(b)	Capital			
()	Investments	63,998	32,243	31,755
	Capital DTLs	63,998	32,243	31,755
(c)	Total DTLs	173,121	32,243	140,878
4.	Net admitted DTAs	\$101,803	\$985,089	\$(883,286)

The change in net deferred income taxes is comprised of the following:

	Decen	December 31,		
	2014	2013	Change	
Total DTAs	\$327,908	\$1,123,420	\$(795,512)	
Total DTLs Net DTAs/(DTLs)	(173,121) \$154,787	(32,243) \$1,091,177	(140,878) (936,390)	
Tax effect of unrealized gains (losses)	4 1 2 1 , 1	4 1,00 1,111		
Change in net deferred income tax			\$(936,390)	

The valuation allowance adjustment to gross DTAs was \$28,036 and \$6,687 for December 31, 2014 and 2013, respectively.

D. The provision (benefit) for federal income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference were as follows:

	D 04 0044	Effective	D 1 04 0040	Effective
	December 31, 2014	tax rate	December 31, 2013	tax rate
Provision (benefit) computed at statutory rate	\$1,001,219	35.0%	\$(624,866)	35.0%
Permanent items, including	102 604	6.8%	(257 205)	20.00/
transfer pricing adjustment Change in nonadmitted assets	193,694 18,401	0.6%	(357,385) (30,977)	20.0% 1.7%
Change in statutory valuation	·		, ,	
allowance adjustment	21,349	0.7%	6,687	(0.4)%
Prior year return to provision adjustment	2,691	0.1%	(63,740)	3.6%
Total	\$1,237,354	43.2%	\$(1,070,281)	59.9%
Federal and foreign income tax expense incurred	\$300,964	10.5%	\$(419,760)	23.5%
Change in net deferred	026 200	22 70/	(GEO E21)	26 40/
income taxes	936,390	32.7%	(650,521) \$(1,070,381)	36.4%
Total statutory income taxes	\$1,237,354	43.2%	\$(1,070,281)	59.9%

The transfer pricing adjustment allows taxpayers to apply different methods to price current period intercompany services at arm's length prices as compared to what would be charged to an unrelated entity, which results in a permanent deduction for tax reporting purposes.

E.

- 1. At December 31, 2014, the Company had no net capital loss or net operating loss carryforwards for tax purposes.
- 2. The amount of federal income taxes incurred that is available for recoupment in the event of future net losses is \$311,325 for the year ended December 31, 2014. There are no federal income taxes incurred that are available for recoupment in the event of future net losses for the year ended December 31, 2013.
- 3. The Company did not report any deposits as admitted assets under Internal Revenue Code Section 6603 at December 31, 2014 and 2013.

F.

Aetna Health Inc. (Michigan)

1. At December 31, 2014, the Company's Federal Income Tax Return was consolidated with the following entities:

Aetna Inc Parent Company	Coventry Health Care of Delaware, Inc.
@ Credentials Inc.	Coventry Health Care of Florida, Inc.
Active Health Management Inc.	Coventry Health Care of Georgia, Inc.
Adminco, Inc.	Coventry Health Care of Illinois, Inc.
Administrative Enterprises, Inc.	Coventry Health Care of Iowa, Inc.
AE Fourteen Incorporated	Coventry Health Care of Kansas, Inc.
Aetna ACO Holdings, Inc.	Coventry Health Care of Louisiana, Inc.
Aetna Better Health Inc. (Connecticut)	Coventry Health Care of Missouri, Inc.
Aetna Better Health Inc. (Florida)	Coventry Health Care of Nebraska, Inc.
Aetna Better Health Inc. (Georgia)	Coventry Health Care of Pennsylvania, Inc.
Aetna Better Health Inc. (Illinois)	Coventry Health Care of Texas, Inc.
Aetna Better Health Inc. (New Jersey)	Coventry Health Care of the Carolinas, Inc.
Aetna Better Health Inc. (New York)	Coventry Health Care of Virginia, Inc.
Aetna Better Health Inc. (Ohio)	Coventry Health Care of West Virginia, Inc.
Aetna Better Health Inc. (Pennsylvania)	Coventry Health Care Workers' Compensation, Inc.
Aetna Better Health Inc. (Tennessee)	Coventry Health Care, Inc.
Aetna Better Health of Michigan Inc.	Coventry Health Plan of Florida, Inc.
Aetna Better Health of Texas Inc.	Coventry HealthCare Management Corporation
Aetna Better Health, Inc. (Louisiana)	Coventry Management Services, Inc.
Aetna Dental Inc. (New Jersey)	Coventry Prescription Management Services, Inc.
Aetna Dental Inc. (Texas)	Coventry Rehabilitation Services, Inc.
Aetna Dental of California Inc.	Coventry Summit Health Plan, Inc.
Aetna Health and Life Insurance Company	Coventry Transplant Network, Inc.
Aetna Health Finance, Inc.	Delaware Physicians Care, Incorporated
Aetna Health Inc. (Connecticut)	First Health Group Corp.
Aetna Health Inc. (Florida)	First Health Life and Health Insurance Company
Aetna Health Inc. (Georgia)	First Script Network Services, Inc.
Aetna Health Inc. (Maine)	Florida Health Plan Administrators, LLC

FOCUS Healthcare Management, Inc.

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation)

Aetna Health Inc. (New Jersey) Aetna Health Inc. (New York) Aetna Health Inc. (Pennsylvania)

Aetna Health Inc. (Texas)

Aetna Health Insurance Company

Aetna Health Insurance Company of New York

Aetna Health of California, Inc. Aetna Health of Utah Inc.

Aetna Insurance Company of Connecticut

Aetna Integrated Informatics, Inc.

Aetna International Inc. Aetna I reland Inc. Aetna I ife & Casualty (R

Aetna Life & Casualty (Bermuda) Ltd. Aetna Life Assignment Company Aetna Life Insurance Company

Aetna Risk Assurance Company of Connecticut, Inc.

Aetna Risk Indemnity Company Limited Aetna Student Health Agency Inc.

AHP Holdings, Inc. Allviant Corporation

American Health Holding, Inc.

AUSHC Holdings, Inc.
Broadspire National Services, Inc.

bSwift, LLC

Cambridge Life Insurance Company Carefree Insurance Services, Inc.

CHC Casualty Risk Retention Group, Inc. Chickering Claims Administrators, Inc. Claims Administration Corporation

Cofinity, Inc.

Corporate Benefit Strategies, Inc. Coventry Consumer Advantage, Inc.

Coventry Financial Management Services, Inc. Coventry Health and Life Insurance Company Coventry Health Care National Accounts, Inc. Coventry Health Care National Network, Inc. Group Dental Service of Maryland, Inc.

Group Dental Service, Inc.

Health and Human Resource Center, Inc. Health Data & Management Solutions, Inc.

Health Re, Incorporated

HealthAmerica Pennsylvania, Inc. HealthAssurance Financial Services, Inc. HealthAssurance Pennsylvania, Inc. HealthCare USA of Missouri, LLC Jaguar Merger Subsidiary, Inc.

Luettgens Limited

Managed Care Coordinators, Inc.

Medicity Inc.

Mental Health Associates, Inc.

Mental Health Network of New York IPA, Inc.

Meritain Health, Inc. MetraComp, Inc.

MHNet Life and Health Insurance Co.

MHNet of Florida, Inc. Niagara Re, Inc. PayFlex Holdings, Inc. PayFlex Systems USA, Inc.

Performax, Inc.

Precision Benefit Services, Inc.

Prime Net, Inc.

Prodigy Health Group, Inc.

Professional Risk Management, Inc.

Resources for Living, LLC

Schaller Anderson Medical Administrators,

Incorporated

Strategic Resource Company
The Vasquez Group Inc.
U.S. Health Care Properties, Inc.
WellPath of South Carolina, Inc.
Work and Family Benefits, Inc.

- 2. As explained in Note 1, the Company participates in a tax sharing agreement with its parent and affiliates.
- G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.
- 10. Information concerning Parent, subsidiaries, affiliates, and other related parties

A., B. and C.

The Company did not pay any dividends or receive capital contributions in 2014 or 2013.

D. Amounts due to and due from affiliates shown in the accompanying Statutory Statements of Assets, Liabilities, Capital and Surplus include the Company's net receipts and disbursements processed by affiliates and transactions related to its administrative services agreement with Aetna Health Management, LLC ("AHM"), indirectly a wholly-owned subsidiary of Aetna.

At December 31, 2014 and 2013, the Company reported \$3,716,535 and \$4,151,258, respectively, as amounts due to AHM. At December 31, 2014 and 2013, the Company did not have any amounts due from affiliates.

The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

- E. At December 31, 2014, the Company did not have any guarantees or undertakings with its affiliates or parent company.
- F. As of and for the years ended December 31, 2014 and 2013, the Company had the following significant transactions with affiliates:

The Company and AHM are parties to an administrative services agreement, under which AHM provides certain administrative services, including accounting and processing of premiums and claims. Under this agreement, the Company remits a percentage of its earned commercial, Medicaid and Medicare premium revenue, as applicable, to AHM as a fee, subject to an annual true-up mechanism as defined in the agreement. Under the agreement, this true-up is due to be settled with the affiliate by April 15th of the

following contract year (which is January 1 to December 31 annually). Effective January 1, 2014, this agreement was amended to include terms and conditions to comply with Medicare laws, regulations and Centers for Medicare & Medicaid Services ("CMS") instructions. For these services, the Company was charged \$11,139,146 and \$13,214,257 in 2014 and 2103, respectively.

This agreement also provides for interest on all intercompany balances. Interest earned on amounts due from affiliates was \$6,506 in 2014 and \$3,577 in 2013. Interest incurred on amounts due to affiliates was 1,937 in 2014 and \$2,837 in 2013.

The Company is a party to an agreement that enables the Company to receive manufacturers' pharmacy rebates from AHM under which the Company remits a percentage of its earned pharmaceutical rebates to AHM as a fee. The Company earned pharmaceutical rebates of \$2,725,221 and \$1,812,429, which were recorded as a reduction of hospital and medical costs, in 2014 and 2013, respectively. The Company incurred pharmaceutical rebate fees, which were recorded as administrative expense, of \$272,522 in 2014 and \$181,242 in 2013. At December 31, 2014 and 2013, the Company reported \$221,447 and \$102,868, respectively, as amounts due from AHM related to pharmaceutical rebates that were reflected in health care and other amounts receivable. The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

The amounts reported on the Underwriting and Investment Exhibit, Part 3 represent the expenses incurred under the terms of the administrative agreement, allocated to the Company in accordance SSAP No. 70, Allocation of Expenses ("SSAP No. 70"). SSAP No. 70 states "shared expenses, including expenses under the terms of a management contract, shall be apportioned to the entities incurring the expense as if the expense had been paid solely by the incurring entity. The apportionment shall be completed based upon specific identification to the entity incurring the expense. Where specific identification is not feasible, apportionment shall be based upon pertinent factors or ratios." The Company allocates these expenses based upon a percentage calculated using actual general and administrative expenses incurred by AHM.

The Company has coverage for certain litigation exposures (\$10,000,000 per claim and in the aggregate including defense costs) through an affiliated captive insurance company.

The Company has an insolvency agreement with Aetna Health Insurance Company ("AHIC"), a wholly-owned subsidiary of Aetna. This agreement provides that in the event that the Company ceases operations or becomes insolvent, AHIC will continue to pay benefits for any members confined as inpatients on the date of insolvency until their discharge. This agreement also provides that AHIC will continue benefits for any member until the end of the contract period for which premium has been paid, but for no longer than thirty-one days. AHIC will also make available to members, for a period of thirty-one days, replacement insurance policies.

As explained in Note 1, the Company participates in a tax sharing agreement with Aetna and Aetna's other subsidiaries. All federal income tax receivables/payables are due from/due to Aetna.

- G. All outstanding shares of the Company are owned by Aetna Health Holdings, LLC, whose ultimate parent is Aetna.
- H. At December 31, 2014, the Company did not hold any investments in any affiliate and did not own shares of any upstream intermediate of Aetna.
- I. At December 31, 2014, the Company did not hold any investments in any subsidiary, controlled or affiliated ("SCA") entity.
- J. At December 31, 2014, the Company did not hold any investments in any impaired SCA entity.
- K. At December 31, 2014, the Company did not hold any investments in any foreign insurance subsidiaries.
- L. At December 31, 2014, the Company did not hold any investments in a downstream noninsurance holding company.

11. <u>Debt</u>

- A. The Company did not have any items related to debt, including capital notes at December 31, 2014.
- B. The Company did not have any Federal Home Loan Bank agreements at December 31, 2014.
- 12. Retirement plans, deferred compensation, postemployment benefits and compensated absences and other postretirement benefit plans

The Company did not have a retirement plan, deferred compensation plan, or other postretirement benefit plan at December 31, 2014 or 2013.

13. Capital and surplus, shareholders' dividend restrictions and quasi-reorganizations

- (1) The Company has 1,000,000 shares of common stock with \$1 par value authorized, issued and outstanding at December 31, 2014 and 2013.
- (2) The Company did not have any preferred stock authorized or outstanding at December 31, 2014 or 2013.

(3) <u>Dividend restrictions</u>

Under the laws of the State of Maine, the Company shall not pay any extraordinary dividend or make any other extraordinary distribution until sixty days after the Maine Department has received notice of the declaration thereof and has not within such period disapproved such payment or the Maine Department has approved such payment within such sixty day period. An extraordinary dividend or distribution includes any dividend or distribution that exceeds the greater of: 10% of such insurer's surplus as regards policyholders as of December 31st of the preceding year; or the net gain from operations for the twelve month period ending December 31st of the preceding year. Ordinary dividends are ultimately limited to earned surplus.

The Company may make a non-extraordinary dividend with prior notification to the Maine Department within five business days following the declaration of any non-extraordinary dividend and at least ten days prior to the payment of any non-extraordinary dividend.

In addition, any dividend or distribution declared at any time within five years following any acquisition of control of a domestic insurer or by any person controlling that insurer is an extraordinary dividend if it has not been approved by a number of continuing directors equal to a majority of the continuing directors in office immediately preceding the acquisition of control.

- (4) The Company did not pay any dividends in 2014 or 2013.
- (5) At December 31, 2014, the portion of the Company's profits that may be paid as ordinary dividends to stockholders was \$2.6 million.
- (6) There were no restrictions placed on the Company's surplus, including for whom the surplus was being held at December 31, 2014 or 2013, except as noted in Note 21.
- (7) Not applicable to the Company.
- (8) The Company did not hold any stock for any special purposes at December 31, 2014 or 2013.
- (9) Changes in the balances of special surplus funds from the prior year are due to the accrual of estimated 2015 ACA health insurer fees reclassified from unassigned funds (surplus) to aggregate write-ins for special surplus funds as discussed more fully in Note 1.C and Note 22.
- (10) At December 31, 2014, there was no portion of unassigned funds (surplus) that was represented or reduced by unrealized gains and (losses).
- (11) The Company has not issued any surplus notes or debentures or similar obligations at December 31, 2014 or 2013.
- (12) The Company did not participate in any quasi-reorganizations during the statement year.
- (13) The Company did not participate in any quasi-reorganizations in the past 10 years.

14. Contingencies

- A. The Company did not have any contingent commitments at December 31, 2014 or 2013.
- B. The Company did not have any contingent assessments at December 31, 2014 or 2013.
- C. The Company did not have any gain contingencies at December 31, 2014 or 2013.
- D. The Company did not have any claims related extra contractual obligation and bad faith losses stemming from lawsuits at December 31, 2014 or 2013.
- E. The Company did not have any joint and several liability arrangements at December 31, 2014 or 2013.
- F. Various liabilities arise in the normal course of the Company's business and have been recorded. In the opinion of management, any ultimate contingent losses will not have a material adverse effect on the Company's future results of operations and financial position. The Company, to the best of its knowledge, has no assets that it considers impaired that are not already recorded in the Company's books.

15. <u>Leases</u>

The Company did not have any material lease obligations at December 31, 2014 or 2013.

16. <u>Information about financial instruments with off-balance sheet risk and financial instruments with concentrations of credit risk</u>

The Company did not have any financial instruments with off-balance sheet risk or financial instruments with concentrations of credit risk at December 31, 2014 or 2013.

17. Sale, transfer and servicing of financial assets and extinguishments of liabilities

A. Transfers of receivables reported as sales

(1) The Company did not have any transfers of receivables as sales for the years ending December 31, 2014 and 2013.

B. Transfer and servicing of financial assets

(1) The Company's policy for requiring collateral or other security for security lending transactions as required in SSAP No. 103 is discussed in Note 1. The Company did not have any loaned securities at December 31, 2014 or 2013.

(2) and (3)

The Company did not have any servicing assets or liabilities at December 31, 2014 or 2013.

- (4) The Company did not have any securitized financial assets at December 31, 2014 or 2013.
- (5) The Company did not have any transfers of financial assets at December 31, 2014 or 2013.
- (6) The Company did not have any transfers of receivables with recourse at December 31, 2014 or 2013.
- (7) The Company did not have any repurchase or reverse repurchase agreements at December 31, 2014 or 2013.

C. Wash sales

(1) The Company did not have any wash sales for the years ending December 31, 2014 or 2013.

18. Gain or loss to the HMO from uninsured plans and the uninsured portion of partially insured plans

- A. The Company did not serve as an Administrative Services Only for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2014.
- B. The Company did not serve as an Administrative Services Contract plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2014.
- C. As of December 31, 2014, the Company had reinsurance receivables and low-income subsidy (cost sharing portion) receivables of \$1,052,494 from CMS, which are accounted for as amounts receivable relating to uninsured plans on the Statutory Statements of Assets, as per SSAP No. 47 *Uninsured Plans*. These items relate to the Company's Medicare product offerings.

19. Direct premium written/produced by managing general agents/third party administrators

The Company did not have any material direct premiums written through/produced by managing general agents or third party administrators for the years ended December 31, 2014 and 2013.

20. Fair value measurements

A. and B.

The Company had no material assets or liabilities measured and reported at fair value at December 31, 2014 or 2013

- C. Certain of the Company's financial instruments are measured at fair value in our balance sheets. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by U.S. generally accepted accounting principles. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies a financial asset or liability for each level:
 - Level 1 Unadjusted quoted prices for identical assets or liabilities in active markets.
 - Level 2 Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
 - Level 3 Developed from unobservable data, reflecting our own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, we use these quoted market prices to determine the fair value of financial assets and liabilities and classify these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, we estimate fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market prices are not available, we determine fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

The carrying values and estimated fair values of the Company's financial instruments at December 31, 2014 and 2013 were as follows:

December 31, 2014

	Aggregate fair value	Admitted assets	Level 1	Level 2	Level 3	Not practicable (carrying value)
Bonds, short-term investments and cash	•					
equivalents	\$23,772,353	\$22,769,232	\$13,605,282	\$10,167,071	-	-
Total	\$23,772,353	\$22,769,232	\$13,605,282	\$10,167,071	-	-

December 31, 2013

	Aggregate fair value	Admitted assets	Level 1	Level 2	Level 3	Not practicable (carrying value)
Bonds, short-term investments and cash	\$20,400,070	(00 544 077	\$47,405.047	\$40.700.004		
equivalents	\$30,193,872	\$29,511,377	\$17,425,647	\$12,768,224	-	-
Total	\$30,193,872	\$29,511,377	\$17,425,647	\$12,768,224	-	-

The valuation methods and assumptions used by the Company in estimating the fair value of debt securities are discussed in Note 1.

There were no material realized and unrealized capital gains, purchases, sales, settlements, or transfers into or out of the Company's Level 3 financial assets during 2014 or 2013.

In evaluating the Company's management of interest rate and liquidity risk and currency exposures, the fair values of all assets and liabilities should be taken into consideration, not only those presented above.

D. The Company did not have any financial instruments where it was not practicable to estimate the fair value.

21. Other items

A. Extraordinary items

The Company did not have any extraordinary items for the years ended December 31, 2014 and 2013.

B. <u>Troubled debt restructuring: debtors</u>

The Company did not have any troubled debt restructuring in the years ended December 31, 2014 and 2013.

C. Other disclosures and unusual items

(1) Minimum capital and surplus

Under the laws of the State of Maine, the Company is required to maintain a minimum capital and surplus equal to the greater of (1) \$1,000,000; (2) 2% of the annual premium revenues as reported by the Company on its most recent annual financial statement filed with the Superintendent for the first \$150,000,000 of premium reported and 1% of the annual premium in excess of the first \$150,000,000 of premium reported; (3) an amount equal to the sum of three months of uncovered health care expenditures as reported on the financial statement covering the Company's immediately preceding fiscal

year as filed with the superintendent; or (4) an amount equal to the sum of 8% of the annual health care expenditures, except those paid on a capitated basis as reported on the financial statement covering the Company's immediately preceding fiscal year as filed with the superintendent. At December 31, 2014 and 2013, the Company's capital and surplus exceeded all such requirements.

The NAIC and the State of Maine adopted risk-based capital ("RBC") standards for health organizations, including HMOs, that are designed to identify weakly capitalized companies by comparing each company's adjusted capital and surplus to its required capital and surplus (the "RBC Ratio"). The RBC Ratio is designed to reflect the risk profile of the company. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring insurers to submit a comprehensive plan to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December 31, 2014 and 2013, the Company had capital and surplus that exceeded the highest threshold specified by the RBC rules.

(2) Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, "Health Care Reform"), enacted in March 2010, has changed and will continue to make broad-based changes to the U.S. health care system which could significantly affect the U.S. economy and which the Company expects will continue to significantly impact the Company's business operations and financial results, including the Company's pricing, medical benefit ratios and the geographies in which the Company's products are available. Health Care Reform presents the Company with new business opportunities, but also with new financial and regulatory challenges. Since its enactment in 2010, key components of Health Care Reform have been phased in, including health insurance exchanges ("Public Exchanges), required minimum MLRs in commercial and Medicare products, the individual coverage mandate, guaranteed issue, rating limits in the individual and small group markets, significant new industry-wide fees, assessments and taxes, enhanced premium rate review and disclosure processes, reduced Medicare Advantage payment rates to insurers, and linking Medicare Advantage payments to a plan's CMS quality performance ratings or "star ratings." The effects of these changes are reflected in the Company's financial results.

While key components of Health Care Reform will continue to be phased in through 2018, the most significant changes occurred in 2014. The Company is dedicating and will continue to be required to dedicate material resources and incur material expenses during 2015 to implement and comply with Health Care Reform as well as state level health care reform. While the federal government has issued a number of regulations implementing Health Care Reform, certain significant parts of Health Care Reform, including aspects of Public Exchanges, Medicaid expansion, enforcement related reporting for the individual and employer mandates, reinsurance, risk corridor, risk adjustment and the implementation of Medicare Advantage and Part D minimum MLRs, require further guidance and clarification at the federal level and/or in the form of regulations and actions by state legislatures to implement the law. The federal government also has announced significant changes to and/or delays in effective dates of various aspects of Health Care Reform, and it is likely that further changes will be made at the federal and/or state level based on implementation experience. As a result, key aspects and impacts of Health Care Reform will not be known for several years, and given the inherent difficulty of foreseeing how individuals and businesses will respond to the choices afforded them by Health Care Reform, the Company cannot predict the full effect Health Care Reform will have on the Company. It is reasonably possible that Health Care Reform, in the aggregate, could have a material adverse effect on the Company's business operations and financial results.

Federal budget negotiations, ongoing regulatory changes to Health Care Reform (such as the November 2013 action permitting renewal through 2014 of individual and small group insurance policies that do not comply with Health Care Reform and the March 2014 action permitting such renewal through 2017), pending efforts in the U.S. Congress to amend or restrict funding for various aspects of Health Care Reform and litigation challenging aspects of the law continue to create uncertainty about the ultimate impact of Health Care Reform. An example of this uncertainty is the litigation pending before the U.S. Supreme Court concerning whether the IRS may make tax credits available as a form of subsidy to individuals who purchase health insurance through Public Exchanges established by the federal government ("Federal Exchanges"). The Company will continue to enroll and insure members through the Federal Exchanges pending the resolution of this and other pending cases. If the payment of subsidies with respect to members who enroll through the Federal Exchanges ultimately is invalidated, it could result in a significant reduction in Aetna's Public Exchange membership because almost all of Aetna's Public Exchange membership is through Federal Exchanges, and most of those members benefit from a tax subsidy.

The availability of funding for Health Care Reform's risk corridor program is a second example of this uncertainty. In May 2014, CMS published a final rule on Public Exchanges. The final rule provides that payments to health plans under the risk corridor program required by Health Care Reform will no longer be limited to the aggregate amount of the risk corridor collections received by HHS over the duration of the risk corridor program. However, it is possible that payments to health plans under the risk corridor program will require additional appropriation legislation to be passed by the U.S. Congress. Additionally,

in December 2014, the Consolidated and Further Continuing Appropriations Act was enacted, which among other things, prohibits HHS's use of certain funds to pay HHS's potential obligation under Health Care Reform's risk corridor program. As a result, the Company did not record any receivable under Health Care Reform's risk corridor program at December 31, 2014.

In addition, the federal and state governments continue to enact and seriously consider many other broad-based legislative and regulatory proposals that have impacted or could materially impact various aspects of the health care system. The Company cannot predict whether pending or future federal or state legislation or court proceedings, including future U.S. Congressional appropriations and the proceedings relating to tax credits for Federal Exchange members described above, will change various aspects of the health care system or Health Care Reform or the impact those changes will have on the Company's business operations or financial results, but the effects could be materially adverse.

In addition, certain provisions of Health Care Reform tie Medicare Advantage plans' premiums to the achievement of favorable CMS quality performance measures ("star ratings"). In 2013 and 2014, Medicare Advantage plans with an overall star rating of three or more stars (out of five stars) are eligible for a quality bonus in their basic premium rates. Beginning in 2015, only Medicare Advantage plans with an overall star rating of four or more stars will be eligible for a quality bonus. As a result, the Company's Medicare Advantage plans' operating results in 2015 and going forward are likely to be significantly determined by their star ratings.

(3) Medicare

The Company's Medicare Advantage products are regulated by CMS. The regulations and contractual requirements applicable to the Company and other participants in Medicare programs are complex, expensive to comply with and subject to change. For example, in the second quarter of 2014, CMS issued a final rule implementing the Health Care Reform requirements that Medicare Advantage plans report and refund to CMS overpayments that those plans receive from CMS. During 2014, CMS also issued a final rule that changes in some respects how the Company can pay pharmacies and impacts the Company's Medicare Advantage products. The Company has invested significant resources to comply with Medicare standards, and the Company's Medicare compliance efforts will continue to require significant resources. CMS may seek premium and other refunds, prohibit the Company from continuing to market and/or enroll members in or refuse to passively enroll members in one or more of the Company's Medicare or Medicare-Medicaid demonstration (historically known as "dual eligible") plans, exclude the Company from participating in one or more Medicare or dual eligible programs and/or institute other sanctions against the Company if the Company fails to comply with CMS regulations or the Company's Medicare contractual requirements.

- D. The Company did not have any business interruption insurance recoveries for the years ending December 31, 2014 or 2013.
- E. The Company did not have any transferable and non-transferable state tax credits for the years ending December 31, 2014 or 2013.
- F. The Company did not have any subprime mortgage related risk exposures at December 31, 2014 or 2013.
- G. The Company did not have any retained assets at December 31, 2014 or 2013.
- H. The Company did not have any joint and several liability arrangements at December 31, 2014 or 2013.

22. Events subsequent

Type I - Recognized subsequent events

Subsequent events have been considered through February 25, 2015 for the statutory statement issued on March 1, 2015.

The Company had no known reportable recognized subsequent events.

Type II - Nonrecognized subsequent events

Subsequent events have been considered through February 25, 2015 for the statutory statement issued on March 1, 2015.

On January 1, 2015, the Company will be subject to an annual fee under section 9010 of the Federal ACA. This annual fee will be allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that is written during the preceding calendar year. A health insurance entity's portion of the annual fee becomes payable once the entity provides health insurance for any U.S. health risk for each calendar year beginning on or after January 1 of the year the fee is due. As of December 31, 2014, the Company has written health insurance subject to the ACA assessment, expects to conduct health insurance business in 2015, and estimates their portion of the annual health insurance industry fee to be payable on September 30, 2015 to be \$2,000,000. This amount is reflected in special surplus. This assessment is expected to impact RBC by 13%. Reporting the ACA assessment as of December 31, 2014, would not have triggered an RBC action level.

		Current year	Prior year
A. B. C. D. E. F. G.	ACA fee assessment payable for upcoming year ACA fee assessment paid Premium written subject to ACA 9010 assessment Total Adjusted Capital before surplus adjustment Authorized Control Level before surplus adjustment Total Adjusted Capital after surplus adjustment Authorized Control Level after surplus adjustment	\$2,000,000 \$1,449,400 \$105,168,193 \$15,669,848 \$4,056,220 \$13,669,848 \$4,056,220	\$1,470,000 - \$98,180,276

Would reporting the ACA assessment as of December 31, 2014, have triggered an RBC action Η. level (YES/NO)?

Nο

23. Reinsurance

Effective April 1, 2014, the Company entered into a quota share reinsurance agreement with Fresenius Medical Care Reinsurance Company (Cayman) LTD, an affiliate of Fresenius Medical Care Holdings, Inc. ("Fresenius") covering Medicare Advantage Plans. Under this agreement, the Company will cede to Fresenius and Fresenius shall reinsure 100% of eligible expenses incurred per program participant per agreement year. The Company paid reinsurance premiums of \$473,144 and realized net reinsurance recoveries of \$473,144 in 2014 related to this agreement.

Ceded Reinsurance Report

Section 1 – General Interrogatories

Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

No (X) Yes()

If yes, give full details.

Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

No() Yes (X) If yes, give full details.

Fresenius is located in the Cayman Islands and is an affiliate of Fresenius Medicare Care Holdings, Inc. (not primarily engaged in the insurance business).

Section 2 - Ceded Reinsurance Report - Part A

Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than nonpayment of premium or other similar credit?

Yes() No (X)

If yes, what is the estimated amount of the aggregate reduction in surplus of a unilateral cancellation by the reinsurer as of the date of this statement, for those agreements in which cancellation results in a net obligation of the reporting entity to the reinsurer, and for which such obligation is not presently accrued? Where necessary, the reporting entity may consider the current or anticipated experience of the business reinsured in making this estimate.

What is the total amount of reinsurance credits taken, whether as an asset or as a reduction of liability for these agreements in this statement?

Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies? No (X)

If yes, give full details.

Yes()

Section 3 – Ceded Reinsurance Report – Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the insurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate.

\$ 0

- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement? Yes () No (X) If yes, what is the amount of reinsurance credit, whether an asset or a reduction of liability, taken for such new agreements or amendments? \$_____N/A____.
- B. The Company did not have uncollectible reinsurance at December 31, 2014.
- C. The Company did not have any commutation of ceded reinsurance at December 31, 2014.
- D. The Company's certified reinsurer's rating has not been downgraded or its status subject to revocation at December 31, 2014.

24. Retrospectively rated contracts and contracts subject to redetermination

- A. Through annual contracts with CMS, the Company offers HMO plans for Medicare-eligible individuals through the Medicare Advantage program. Members typically receive enhanced benefits over standard Medicare fee-for-service coverage, including reduced cost-sharing for preventative care, vision and other non-Medicare services. Members also typically receive coverage for certain prescription drugs, usually subject to a deductible, co-insurance and/or co-payment. The revenues ultimately received by the Company for each member are based on that member's health status and demographic characteristics, as determined via the CMS risk adjustment process, under which the Company regularly submits risk adjustment data to CMS. As such, at December 31, 2014 the Company records a receivable for future revenues that it expects to receive from CMS in the 3rd quarter of 2015, after the final reconciliation of risk adjustment data for contract year 2014 is complete. The Company estimates this receivable by taking into account risk adjustment data for contract year 2014 submitted to CMS prior to December 31, 2014, as well as its estimate of the impact of risk adjustment data for contract year 2014 that will be submitted prior to the appropriate regulatory deadline in early 2015. These amounts are recognized in 2014 as premiums under contracts subject to redetermination. In addition, the Company's Medicare Advantage contracts are subject to retrospective rating provisions under which the Company and CMS share in amounts above and below agreed-upon target medical benefit ratios.
- B. The Company had net premiums written of \$61,758,085 and \$41,342,928 related to its agreements with CMS for the years ended December 31, 2014 and 2013, respectively, representing 59% for 2014 and 42% for 2013 of total premium revenue. The Company had net premiums receivable of \$2,418,067 and \$2,130,173 related to its agreements with CMS as of December 31, 2014 and 2013, respectively, representing 75% in 2014 and 76% in 2013 of total premiums receivable.
- C. Contracts subject to redetermination

The Company did not have any contracts subject to redetermination in 2014 or 2013.

D. <u>Medical loss ratio rebates required pursuant to the Public Health Service Act</u>

The Company is required to make premium rebate payments to customers that are enrolled under certain health insurance policies if specific minimum annual MLR are not met in the prior year. The Company's results for full-years 2014 and 2013 included an estimate of \$48 and \$405, respectively, of minimum MLR rebates, which were included in aggregate health policy reserves in the Statutory Statements of Liabilities , Capital and Surplus. The Company paid \$528,890 of minimum MLR rebates in 2014 for the year 2013. The Company had no payments in 2013.

	Individual	Small group employer	Large group employer	Other categories with rebates	Total
Prior reporting year					
(1) Medical loss ratio					
rebates incurred	_	_	\$(110,743)	_	\$(110,743)
(2) Medical loss ratio			4(****)		+ (****,*****)
rebates paid	-	-	-	-	-
(3) Medical loss ratio					
rebates unpaid	-	-	\$405	-	\$405
(4) Plus reinsurance					
assumed amounts	XXX	XXX	XXX	XXX	-
(5) Less reinsurance					
ceded amounts	XXX	XXX	XXX	XXX	-
(6) Rebates unpaid net	X /X/	\/\/\/	\/\/\/	X /X//	# 40 =
of reinsurance	XXX	XXX	XXX	XXX	\$405
Current reporting year-to-date					
(7) Medical loss ratio					
rebates incurred	_	\$266,427	\$262,106	_	\$528,533
(8) Medical loss ratio		Ψ200, 121	Ψ202,100		ψ020,000
rebates paid	-	\$266,427	\$262,463	-	\$528,890
(9) Medical loss ratio					
rebates unpaid	-	-	\$48	-	\$48
(10) Plus reinsurance					
assumed amounts	XXX	XXX	XXX	XXX	-
(11) Less reinsurance					
ceded amounts	XXX	XXX	XXX	XXX	-
(12) Rebates unpaid net	V /V/	\/\/\/	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	X /X//	# 40
of reinsurance	XXX	XXX	XXX	XXX	\$48

E. Risk Sharing Provisions of the Affordable Care Act

Line items below where the amount is zero are due to no activity as of the reporting date.

⁽¹⁾ Did the reporting entity write accident and health insurance premium which is subject to the ACA risk sharing provisions (YES/NO)? Yes

(2) Impact of Risk Sharing Provisions of the ACA on Admitted Assets, Liabilities and Revenue and Expenses for the Current Year:

	Degree on eart A.C.A. Diels Adivistment Description	Amount
a.	Permanent ACA Risk Adjustment Program	
	Assets 1. Premium adjustments receivable due to ACA Risk Adjustment	-
	Liabilities 2. Risk adjustment user fees payable for ACA Risk Adjustment 3. Premium adjustments payable due to ACA Risk Adjustment	
	Operations (Revenue & Expense) 4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment 5. Reported in expenses as ACA Risk Adjustment user fees (incurred/paid)	-
b.	Transitional ACA Reinsurance Program	
٠.	•	
	Assets 1. Amounts recoverable for claims paid due to ACA Reinsurance 2. Amounts recoverable for claims unpaid due to ACA Reinsurance (contra liability)	-
	Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	-
	Liabilities 4. Liabilities for contributions payable due to ACA Reinsurance not reported as ceded premium	\$113,722
	 5. Ceded reinsurance premiums payable due to ACA Reinsurance 6. Liabilities for amounts held under uninsured plans contributions for ACA Reinsurance 	φ113,722 - -
	Operations (Revenue & Evange)	
	 Operations (Revenue & Expense) 7. Ceded reinsurance premiums due to ACA Reinsurance 8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments 	-
	ACA Reinsurance contributions - not reported as ceded premium	\$(682,332)
C.	Temporary ACA Risk Corridors Program	
	Assets 1. Accrued retrospective premium due to ACA Risk Corridors	-
	Liabilities	
	 Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors 	-
	Operations (Revenue & Expense) 3. Effect of ACA Risk Corridors on net premium income (paid/received) 4. Effect of ACA Risk Corridors on change in reserves for rate credits	- -

(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance.

		Accrued during the prior		Received or paid as of the		
		year on business written		current year on business		
		before Dece	mber 31 of	written before	e December	
		the prio	r year	31 of the prior year		
		1	2	3	4	
		Receivable	(Payable)	Receivable	(Payable)	
a.	Permanent ACA Risk Adjustment Program					
	Premium adjustments receivable	-	-	-	-	
	Premium adjustments (payable)	-	-	-	-	
	3 Subtotal ACA Permanent Risk					
	Adjustment Program	-	-	-	-	
b.	Transitional ACA Reinsurance Program		-	-	-	
	 Amounts recoverable for claims paid 	-	-	-	-	
	Amounts recoverable for claims					
	unpaid (contra liability)	-	-	-	-	
	Amounts receivable relating to					
	uninsured plans	-	-	-	-	
	 Liabilities for contributions payable 					
	due to ACA reinsurance - not					
	reported as ceded premium	-	-	-	-	
	Ceded reinsurance premiums payable	-	-	-	-	
	Liability for amounts held under					
	uninsured plans	-	-	-	-	
	7. Subtotal ACA Transitional					
	Reinsurance Program	-	-	-	-	
C.	Temporary ACA Risk Corridors Program		-	-	-	
	Accrued retrospective premium	-	-	-	-	
	Reserve for rate credits or					
	policy experience rating refunds	-	-	-	-	
	3. Subtotal ACA Risk Corridors Program	-	-	-	-	
	T + 1 (AOA B' 1 OL + B - + +					
d.	Total for ACA Risk Sharing Provisions	-	-	-	-	

		Differences Adjustments				
		Prior year	Prior year			
		accrued	accrued			
		less	less	To prior	To prior	
		payments	payments	year	year	
		(Col 1 - 3)	(Col 2 - 4)	balances	balances	
		5	6	7	8	
		Receivable	(Payable)	Receivable	(Payable)	Ref
a.	Permanent ACA Risk Adjustment Program					N 1/A
	Premium adjustments receivable	-	-	-	-	N/A
	2. Premium adjustments (payable)	-	-	-	-	N/A
	3 Subtotal ACA Permanent Risk					NI/A
	Adjustment Program	-	-	-	-	N/A
b.	Transitional ACA Reinsurance Program					
	1. Amounts recoverable for claims paid	-	-	-	-	N/A
	2. Amounts recoverable for claims					
	unpaid (contra liability)	-	-	-	-	N/A
	3. Amounts receivable relating to					
	uninsured plans	-	-	-	-	N/A
	 Liabilities for contributions payable 					
	due to ACA reinsurance - not					
	reported as ceded premium	-	-	-	-	N/A
	Ceded reinsurance premiums payable	-	-	-	-	N/A
	Liability for amounts held under					
	uninsured plans	-	-	-	-	N/A
	7. Subtotal ACA Transitional					
	Reinsurance Program	-	-	-	-	N/A
c.	Temporary ACA Risk Corridors Program					
٥.	Accrued retrospective premium	_	-	-	_	N/A
	Reserve for rate credits or					,,
	policy experience rating refunds	_	-	-	-	N/A
	Subtotal ACA Risk Corridors Program	_	-	-	-	N/A
d.	Total for ACA Risk Sharing Provisions	-	-	-	-	N/A

Differences

Adjustments

		Unsettled balances as of the reporting date		
		Cumulative balance	Cumulative balance	
		from prior years	from prior years	
		(col 1 - 3 + 7)	(col 2 - 4 + 8)	
		9	10	
		Receivable	(Payable)	
a.	Permanent ACA Risk Adjustment Program 1. Premium adjustments receivable 2. Premium adjustments (payable) 3 Subtotal ACA Permanent Risk Adjustment Program	- - -	- - -	
b.	Transitional ACA Reinsurance Program Amounts recoverable for claims paid Amounts recoverable for claims Amounts recoverable for claims	-	-	
	unpaid (contra liability) 3. Amounts receivable relating to uninsured plans	- -	- -	
	Liabilities for contributions payable due to ACA reinsurance - not reported as ceded premium	-	-	
	5. Ceded reinsurance premiums payable6. Liability for amounts held under	-	-	
	uninsured plans 7. Subtotal ACA Transitional Reinsurance Program	-	-	
C.	 Temporary ACA Risk Corridors Program Accrued retrospective premium Reserve for rate credits or policy experience rating refunds 	-	-	
	3. Subtotal ACA Risk Corridors Program	-	-	

25. Change in incurred claims and claims adjustment expense

Total for ACA Risk Sharing Provisions

The following table shows the components of the change in claims unpaid, unpaid claims adjustment expense and aggregate health claim reserves for the years ended December 31, 2014 and 2013.

(in thousands)	2014	2013
Balance, January 1 Health care receivable	\$9,566 (103)	\$7,876 (140)
Balance, January 1, net of health care receivable	9,463	7,736
Incurred related to:		
Current year	94,001	86,386
Prior years	(1,347)	486
Total incurred	92,654	86,872
Paid related to:		
Current year	86,646	77,380
Prior years	7,938	7,765
Total paid	94,584	85,145
Balance, December 31, net of health care receivable	7,533	9,463
Health care receivable	221	103
Balance, December 31	\$7,754	\$9,566

In 2014, reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years decreased by approximately \$1.3 million from approximately \$9.5 million in 2013 to approximately \$8.2 million in 2014. In 2013, reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years increased by approximately \$0.5 million from approximately \$7.9 million in 2012 to approximately \$8.4 million in 2013. The lower than anticipated health care cost trend rates observed in 2014 for claims incurred in 2013 were due to moderating outpatient and physician trends and faster than expected claim payment speed. The higher than expected claim intensity and slower than expected claim payment speed. The Company considers historical trend rates together with knowledge of recent events that may impact current trends when developing estimates of current trend rates. Original estimates are increased or decreased as additional information becomes known regarding individual claims. Historical health care cost trend rates are not necessarily representative of current trends. The Company experienced approximately \$9.9 million of favorable prior year claim development on retrospectively rated policies, which is included in the 2013 increase. However, the business to which it relates is subject to premium adjustments. The Company excluded the impact of the change in health care receivables related to pharmacy rebates from the above roll-forward to conform to NAIC Annual Statement presentation.

Net coordination of benefits are implicit in the claims incurred but not reported calculation and could not be specifically identified.

26. Intercompany pooling arrangements

The Company did not have any intercompany pooling arrangements at December 31, 2014 or 2013.

27. Structured settlements

Not applicable to health entities.

28. Health care receivables

A. <u>Pharmaceutical rebate receivables</u>

The Company receives pharmaceutical rebates through an agreement with AHM. AHM has contractual agreements with pharmaceutical companies for rebates, which cover the Company's membership as well as the membership of other Aetna affiliates. The Company receives those rebates from AHM that relate to the Company's membership. The Company estimates pharmaceutical rebate receivables based upon the historical payment trends, actual utilization and other variables. Actual rebates collected are applied to the collection periods below, using a first in, first out methodology. At December 31, 2014 and 2013, the Company had pharmaceutical rebate receivables of \$221,448 and \$102,868, respectively (refer to the Company's accounting practices related to pharmaceutical rebate receivables in Note 1).

The following table discloses the quarterly revenue and subsequent cash collections relating to the pharmaceutical rebates discussed in Note 10.

Quarter	Estimated pharmacy rebates as reported on financial statements	Pharmacy rebates as invoiced/ confirmed	Actual rebates collected within 90 days of invoicing/ confirmation	Actual rebates collected within 91 to 180 days of invoicing/confirmation	Actual rebates collected more than 180 days after invoicing/confirmation
			. 1		
12/31/2014	\$654,910	-	\$433,462 ¹	-	-
9/30/2014	\$681,026	\$727,864	\$727,864	-	-
6/30/2014	\$619,482	\$671,827	\$671,827	-	-
3/31/2014	\$626,265	\$623,499	\$623,499	-	-
	.		.		
12/31/2013	\$525,902	\$573,024	\$573,024	-	-
9/30/2013	\$540,484	\$493,832	\$493,832	-	-
6/30/2013	\$458,872	\$436,772	\$436,772	-	-
3/31/2013	\$373,128	\$374,181	\$374,181	-	-
12/31/2012	\$364,139	\$345,881	\$345,881		
			· · · · · · · · · · · · · · · · · · ·	-	-
9/30/2012	\$332,637	\$354,560	\$354,560	-	-
6/30/2012	\$345,731	\$353,333	\$353,333	-	-
3/31/2012	\$347,812	\$348,111	\$348,111	-	-

¹ Represents a portion of the estimated rebates for the quarter ending December 31, 2014, which were paid by AHM to the Company prior to December 31, 2014 and invoicing in 2015.

B. Risk sharing receivables

The Company did not have any admitted risk sharing receivables at December 31, 2014 or 2013.

29. Participating policies

The Company did not have any participating policies at December 31, 2014 or 2013.

30. Premium deficiency reserves

December 31, 2014

Liability carried for premium deficiency reserves
 Date of the most recent evaluation of this liability
 Was anticipated investment income utilized in the calculation?

31. Anticipated salvage and subrogation

See discussion of hospital and medical costs and claims adjustment expenses and related reserves in Note 1.

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES - GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer?	Yes [X]	No[]
1.2	If yes, complete Schedule Y, Parts 1, 1A and 2. If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards		
1.3	and disclosure requirements substantially similar to those required by such Act and regulations? Yes [X] State regulating? Maine	No []	N/A []
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?	Yes[]	No [X]
2.2	If yes, date of change:	N/A	
3.1 3.2	State as of what date the latest financial examination of the reporting entity was made or is being made. State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity.	12/31/201	0
	This date should be the date of the examined balance sheet and not the date the report was completed or released.	12/31/201	0
3.3	State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date). By what department or departments?	03/01/201	2
	Maine Bureau of Insurance		
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement		
3.6	filed with departments? Have all of the recommendations within the latest financial examination report been complied with? Yes [] Yes []	No [] No []	N/A [X] N/A []
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination		
	thereof under common control (other than salaried employees of the reporting entity) receive credit or commissions for or control a substantial		
	part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?	Yes[]	No [X]
	4.12 renewals?	Yes []	No[X]
4.2	During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate,		
	receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:	V []	Na CV 1
	4.21 sales of new business? 4.22 renewals?	Yes[] Yes[]	No [X] No [X]
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?	Yes []	No [X]
5.2	If yes, provide the name of the entity, NAIC company code, and state of domicile (use two letter state abbreviation) for any entity that has ceased		
	to exist as a result of the merger or consolidation.		
	Name of Entity NAIC Co. Code State of Domicile		
	N/A		
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?	Yes[]	No [X]
6.2	If yes, give full information:	. 55 []	[]
	N/A		
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?	Yes []	No [X]
7.2	If yes,		0.000.0/
	 7.21 State the percentage of foreign control		.0.000 %
	the nationality of its manager or attorney-in-fact and identify the type of entity(ies) (e.g., individual,		
	corporation, government, manager or attorney-in-fact)		
	1 2 Nationality Type of Entity		
	N/A		
8.1	Is the company a subsidiary of a bank holding company regulated by the Federal Reserve Board?	Yes []	No [X]
8.2	If response to 8.1 is yes, please identify the name of the bank holding company. N/A		
0.0			N. 57/3
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities firms? If response to 8.3 is yes, please provide the names and locations (city and state of the main office) of any affiliates regulated by a federal	Yes []	No [X]
	financial regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal		
	Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.		
	1 2 3 4 5 6 Affiliate Name Location (City, State) FRB OCC FDIC SEC		
	N/A		
9.	What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?		
	KPMG LLP, One Financial Plaza, 755 Main Street, Hartford, CT 06103		
10.1	Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant		
	requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation?	Yes[]	No [X]
10.2	If the response to 10.1 is yes, provide information related to this exemption: N/A	-	-
10.3	Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 17A of the Model Regulation, or substantially similar state law or regulation?	Yes []	No [X]
10.4	If the response to 10.3 is yes, provide information related to this exemption: N/A	[]	. [.,]

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) GENERAL INTERROGATORIES

	PART 1 - COMMON INTERROGATORIES Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance If the answer to 10.5 is no or n/a, please explain. N/A		No []	N/A []	_
11.	What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant ass consulting firm) of the individual providing the statement of actuarial opinion/certification? William R. Jones, Valuation Actuary, 151 Farmington Avenue, RE2R; Hartford, CT 06156	ociated with an actuarial			-
12.1	Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate 12.11 Name of real estate holding company N/A	indirectly?	Yes[]	No [X]	-
12.2	12.12 Number of parcels involved 12.13 Total book/adjusted carrying value If yes, provide explanation. N/A		\$		- -
13. 13.1	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY: What changes have been made during the year in the United States manager or the United States trustees N/A	s of the reporting entity?			-
13.2	Does this statement contain all business transacted for the reporting entity through its United States Branch	h on risks wherever located?	Yes []	No []	=
13.3	Have there been any changes made to any of the trust indentures during the year?		Yes[]	No []	
13.4 14.1	If answer to (13.3) is yes, has the domiciliary or entry state approved the changes? Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or c	Yes []	No []	N/A [X]	
14.1	of the reporting entity subject to a code of ethics, which includes the following standards? a. Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest b. Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed	t between personal and professional relationshi	Yes [X]	No []	
	c. Compliance with applicable governmental laws, rules and regulations;	- ay and reparently arrang			
	d. The prompt internal reporting of violations to an appropriate person or persons identified in the cod	le; and			
14.11	e. Accountability for adherence to the code. If the response to 14.1 is no, please explain: N/A N/A				_
	Has the code of ethics for senior managers been amended? If the response to 14.2 is yes, provide information related to amendment(s). The Code of Conduct was amended effective September 2014. The key substantive changes include:		Yes [X]	No []	_
	Clarification that intimidation against anyone who reports a concern is prohibited; The specific listing of fraud, waste and abuse as matters that should be reported to the appropriate persons	nel to more closely align the Code			= =
	of Conduct with CMS requirements; Additional examples in the Conflicts of Interests and Business Expenses sections to reflect questions frequ	ently asked by employees since 2011: and			=
	Additional information on the limitations on the personal political and lobbying activities to which Aetna emp	ployees and their family members are subject.			- -
	Have any provisions of the code of ethics been waived for any of the specified officers? If the response to 14.3 is yes, provide the nature of any waiver(s). N/A		Yes[]	No [X]	_
15.1	Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing	or confirming bank is not on the			-
15.2	SVO Bank List? If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the nof the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.		Yes[]	No [X]	٦
	1 American Bankers	3	4		
		stances That Can Trigger	A	.1	
	Routing Number Bank Name t 0 N/A	the Letter of Credit	Amour	0	
16. 17. 18.	PART 1 - COMMON INTERROGATORIES - B Is the purchase or sale of all investments of the reporting entity passed upon either by the Board of Directors Does the reporting entity keep a complete permanent record of the proceedings of its Board of Directors Has the reporting entity an established procedure for disclosure to its Board of Directors or trustees of an on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely of such person?	ctors or a subordinate committee thereof? and all subordinate committees thereof? ny material interest or affiliation	١	/es[X] /es[X] /es[X]	No [] No []
19. 20.1	PART 1 - COMMON INTERROGATOR Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans):		eles)?	Yes[]	No [X]
_V.1	20.11 To directors or other officers				
	20.12 To stockholders not officers 20.13 Trustees, supreme or grand (Fraternal only)				
20.2	Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy	loans):			
	20.21 To directors or other officers20.22 To stockholders not officers		\$ \$		0 0
21.4	20.23 Trustees, supreme or grand (Fraternal only) Were any assets reported in this statement subject to a contractual obligation to transfer to another party	without the liability for	\$		0
	such obligation being reported in the statement?	, without the liability for		Yes[]	No [X]
21.2	If yes, state the amount thereof at December 31 of the current year: 21.21 Rented from others		.\$		Λ
	21.22 Borrowed from others		\$		0
	21.23 Leased from others 21.24 Other		\$ <u>\$</u>		0

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) PART 1 - COMMON INTERROGATORIES - FINANCIAL

22.1	Does this statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for assessments as described as the statement include payments for a statement include payments and the statement include payments as the statement include payments and the statement include payments are statement in the statement include payments as the statement include payment in the statement include payment in the statement include payment in the statement in th	ibed in the Annual Statement Instructions other the	than guaranty			
	fund or guaranty association assessments?				Yes [X] No []
22.2	If answer is yes: 22.21 Amount paid as losses or risk adjustment			\$	245,029	ı
	22.22 Amount paid as losses of risk adjustment 22.22 Amount paid as expenses			\$	20,013	_
	22.23 Other amounts paid			\$		
23.1	Does the reporting entity report any amounts due from parent, s		nt?	¢	Yes[] No[X	
23.2	If yes, indicate any amounts receivable from parent included in t	ne Page 2 amount.		<u>\$</u>		_
	DADT 4	AAMAN INTERRAATARIEA III	W/FOTMENT			
04.04		COMMON INTERROGATORIES - IN				
24.01	Were all the stocks, bonds and other securities owned December in the actual possession of the reporting entity on said date (other				Yes[X] No[1
24.02	If no, give full and complete information relating thereto.	3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3	,			•
	N/A					
24.02	For security lending programs, provide a description of the progra	m including value for colleteral and amount of loan	nod acqurition, and who	thor		
24.03	collateral is carried on or off-balance sheet (an alternative is to ref			u iei		
	See Notes to Financial Statement - Note 17, Sale, transfer and se					
04.04	Described to the second	the form of the control of the contr				
24.04	Does the company's security lending program meet the requiremental Risk-Based Capital Instructions?	ents for a conforming program as outlined in the		Yes [X]	No [] N/A [1
24.05	If answer to 24.04 is yes, report amount of collateral for conforming	g programs.		100[X]	\$	•
24.06	If answer to 24.04 is no, report amount of collateral for other progr	rams.			\$	
24.07	Does your securities lending program require 102% (domestic secontset of the contract?	curities) and 105% (foreign securities) from the co	unterparty at the	V20 [V]	1 A\/A	1
24 08	Does the reporting entity non-admit when the collateral received fi	rom the counterparty falls below 100%?		Yes [X] Yes [X]	No [] N/A [No [] N/A [-
	Does the reporting entity or the reporting entity's securities lending		ement (MSLA)	.00[71]	[][,
	to conduct securities lending?			Yes [X]	No [] N/A []
24.10	For the reporting entity's security lending program, state the amount 24.101 Total fair value of reinvested collateral assets reported on		int year:		•	١
	24.102 Total book adjusted/carrying value of reinvested collatera				\$	<u></u>
	24.103 Total payable for securities lending reported on the liabilit	y page.			\$	1
25.1	Were any of the stocks, bonds or other assets of the reporting ent			•		
	control of the reporting entity or has the reporting entity sold or tra (Exclude securities subject to Interrogatory 21.1 and 24.03)	nsferred any assets subject to a put option contrac	ct that is currently in for	ce?	Yes[X] No[1
25.2	If yes, state the amount thereof at December 31 of the current year	ar:			ros[x] no[1
	25.21 Subject to repurchase agreements				\$	1
	25.22 Subject to reverse repurchase agreements				\$	_
	25.23 Subject to dollar repurchase agreements 25.24 Subject to reverse dollar repurchase agreements				\$ \$	
	25.25 Placed under option agreements				\$	
	25.26 Letter stock or securities restricted as to sale - excluding	FHLB Capital Stock			\$	_
	25.27 FHLB Capital Stock 25.28 On deposit with states				\$	_
	25.29 On deposit with other regulatory bodies				\$0	-
	25.30 Pledged as collateral - excluding collateral pledged to an				\$	
	25.31 Pledged as collateral to FHLB - including assets backing 25.32 Other	funding agreements			\$	
25.3	For category (25.26) provide the following:				\$0	_
	1	2		3		
	Nature of Restriction	Description		Amount		
26.1	N/A Does the reporting entity have any hedging transactions reported	on Schedule DB?		0	Yes[] No[X	1
	If yes, has a comprehensive description of the hedging program b			Yes []	No[] N/A[X	-
	If no, attach a description with this statement.					
	N/A					
27.1	Were any preferred stocks or bonds owned as of December 31 of	the current year mandatorily convertible into equit	ity, or, at the option of th	ie		
	issuer, convertible into equity?				Yes [] No [X]
	If yes, state the amount thereof at December 31 of the current year.		v in the reporting entity!	offices	\$C	_
28.	Excluding items in Schedule E-Part 3-Special Deposits, real estat vaults or safety deposit boxes, were all stocks, bonds and other si					
	with a qualified bank or trust company in accordance with Section	1, III - General Examination Considerations, F. O.				
20.01	Custodial or Safekeeping Agreements of the NAIC Financial Conc				Yes [X] No []
28.01	For agreements that comply with the requirements of the NAIC Fi	nancial Condition Examiners Handbook, complete	the following:			
	Name of Custodian(s)	Custodiar	n's Address			
	State Street Bank and Trust Company	State Street Financial Center, One Lincoln Street	t; Boston, MA 02111-29	000		
28.02	For all agreements that do not comply with the requirements of the	e NAIC Financial Condition Examiners Handbook,	, provide the			
	name, location and a complete explanation:					-1
		2		3		
	1			Complete Exp	lanation(s)	
	Name(s)	Location(s)				\dashv
20.00	Name(s) All agreements comply.		or?		Vool 1 NetV	
	Name(s) All agreements comply. Have there been any changes, including name changes, in the cu		ar?		Yes[] No[X]
	Name(s) All agreements comply. Have there been any changes, including name changes, in the cu If yes, give full and complete information relating thereto:	stodian(s) identified in 28.01 during the current ye		A	Yes [] No [X]
	Name(s) All agreements comply. Have there been any changes, including name changes, in the cu If yes, give full and complete information relating thereto:		3	4 Reass		
	Name(s) All agreements comply. Have there been any changes, including name changes, in the cu If yes, give full and complete information relating thereto:	stodian(s) identified in 28.01 during the current year				
28.04	Name(s) All agreements comply. Have there been any changes, including name changes, in the culf yes, give full and complete information relating thereto: 1 Old Custodian	stodian(s) identified in 28.01 during the current ye	3 Date of Change			
28.04	Name(s) All agreements comply. Have there been any changes, including name changes, in the culf yes, give full and complete information relating thereto: 1 Old Custodian N/A	stodian(s) identified in 28.01 during the current ye. 2 New Custodian ng on behalf of broker/dealers that have access to	3 Date of Change			
28.04	Name(s) All agreements comply. Have there been any changes, including name changes, in the culf yes, give full and complete information relating thereto: 1 Old Custodian N/A Identify all investment advisors, brokers/dealers or individuals active.	stodian(s) identified in 28.01 during the current ye. 2 New Custodian ng on behalf of broker/dealers that have access to	3 Date of Change			
28.04	Name(s) All agreements comply. Have there been any changes, including name changes, in the culf yes, give full and complete information relating thereto: 1 Old Custodian N/A Identify all investment advisors, brokers/dealers or individuals activated accounts, handle securities and have authority to make investment 1 Central Registration Depository Number(s)	stodian(s) identified in 28.01 during the current yes 2 New Custodian ng on behalf of broker/dealers that have access to this on behalf of the reporting entity:	3 Date of Change	Reas	on	
28.04	Name(s) All agreements comply. Have there been any changes, including name changes, in the culf yes, give full and complete information relating thereto: 1 Old Custodian N/A Identify all investment advisors, brokers/dealers or individuals activated accounts, handle securities and have authority to make investment	stodian(s) identified in 28.01 during the current yes 2 New Custodian ng on behalf of broker/dealers that have access to the son behalf of the reporting entity: 2 Name	3 Date of Change o the investment	Reason 3	on	

27.2

Yes[] No[X]

Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5 (b) (1)])?

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) PART 1 - COMMON INTERROGATORIES - INVESTMENT

29.2	If yes, complete the following schedule:	17.1.(1.1.					_	
	1		2			3	=	
	CUSIP#		Name of Mu	itual Fund		Book/Adjusted Carrying Value		
			0	-				
	29.2999. TOTAL	.,,,				0	-	
29.3	For each mutual fund listed in the table abo	ve, complete the follow	ring schedule:				1	
	1 Name of Mutual Fund		Na	2 me of Significant Holdi	ng	3 Amount of Mutual Fund's Book/Adjusted Carrying Value	4	
	(from the above table))		of the Mutual Fund		Attributable to Holding	Date of Va	luation
	N/A					0		
30.	Provide the following information for all short	rt-term and long-term b	onds and all preferred sto			ement value for fair value.		
			1	2	3			
					Excess of Statement			
			Statement		over Fair Value (-),			
			(Admitted)	Fair	or Fair Value over			
			Value	Value	Statement (+)			
	30.1 Bonds		22,769,232	23,772,353	1,003,121			
	30.2 Preferred stocks		0	0	0			
	30.3 Totals		22,769,232	23,772,353	1,003,121			
31.1 31.2 31.3 32.1 32.2	If the answer to 31.1 is yes, does the report brokers or custodians used as a pricing soul of the answer to 31.2 is no, describe the report N/A Have all the filing requirements of the Purport	uoted or an internal and ortized cost which appr termined by a broker or ing entity have a copy or irce? orting entity's process f	alysis of each investment roximates fair value. The r custodian for any of the of the broker's or custodia for determining a reliable	's financial performanc carrying value of cash securities in Schedule an's pricing policy (hard pricing source for purp	e and cash flow projectic equivalents approximate D? If copy or electronic copy oses of disclosure of fair	ons. Short es fair value. r) for all	Yes [X] Yes [X] Yes [X]	No[] No[]
33.1 33.2	, ,	service organizations a	payment represented 25	reaus, if any? % or more of the total p	payments to		<u>\$</u>	8,625
			1			2 Amount Roid		
	Council for Affordable Quality Healthcare	Γ	Name			Amount Paid 2,490	1	
34.1	Amount of payments for legal expenses, if a	any?				2,430	\$	26,174
34.2		id if any such payment		re of the total payments	5	2	1	
		١	1 Name			2 Amount Paid		
	N/A	·	TOTAL			Amount Faid 0	-	
35.1	Amount of payments for expenditures in cor	nnection with matters b	efore legislative bodies,	officers or departments	of government, if any?	· · · · · · · · · · · · · · · · · · ·	\$	0
35.2		iid if any such payment	represented 25% or mor	re of the total payment	expenditures			
	III COMMON WILLI MALLETS DETOTE TEGISTALIVE	, podies, dilicers di del	1	adming the period cove	iou by this statement.	2	1	
			l Namo			Amount Daid		

0

N/A

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1	Does the reporting entity have any direct Medicare Supplement Insurance in force?	Yes[]	No [X]
1.2	If yes, indicate premium earned on U.S. business only What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit? 1.31 Reason for excluding N/A	\$ \$	0
	N/A	· -	
1.4 1.5	Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above. Indicate total incurred claims on all Medicare Supplement insurance.	\$ \$,
1.6	Individual policies: Most current three years: 1.61 Total premium earned	\$	0
	1.62 Total incurred claims 1.63 Number of covered lives All years prior to most current three years:	\$	
	 1.64 Total premium earned 1.65 Total incurred claims 1.66 Number of covered lives 	\$	0
1.7	Group policies: Most current three years: 1.71 Total premium earned 1.72 Total incurred claims 1.73 Number of covered lives All years prior to most current three years: 1.74 Total premium earned 1.75 Total incurred claims	\$\$ \$\$	0
	1.76 Number of covered lives		0
2.	Health test: 1 2 Current Year Prior Year		
3.1	Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, and if the earnings of the reporting entity permits?	Voc []	No [X]
3.2	If yes, give particulars: N/A	Yes[] -	NO[X]
4.1 4.2 5.1 5.2	Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency? If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered? Does the reporting entity have stop-loss reinsurance? If no, explain: The Company does not have stop loss reinsurance.	Yes[X] Yes[] Yes[]	No [] No [X] No [X]
5.3	Maximum retained risk (see instructions):		
	5.31 Comprehensive medical5.32 Medical only	\$ 	
	 5.33 Medicare supplement 5.34 Dental and vision 5.35 Other limited benefit plan 5.36 Other 	\$ \$ \$	0
6.	Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:	Ψ	
	Provider contracts contain hold harmless and continuity of coverage provisions. In addition, the HMO maintains an insolvency protection agreement with an affiliate of the HMO.	: -	
7.1 7.2	Does the reporting entity set up its claim liability for provider services on a service date basis? If no, give details: N/A	Yes[X]	No[]
8.	Provide the following information regarding participating providers: 8.1 Number of providers at start of reporting year	-	9,415
9.1	8.2 Number of providers at end of reporting year Does the reporting entity have business subject to premium rate guarantees?	Yes []	10,093 No [X]
9.1	If yes, direct premium earned: 9.21 Business with rate guarantees between 15-36 months	\$	0
10.1	9.22 Business with rate guarantees over 36 months Does the reporting entity have Incentive Pool, Withhold or Bonus arrangements in its provider contracts?	\$ Yes[X]	
	If yes:	\$	
	10.22 Amount actually paid for year bonuses	\$	0
	·	\$ \$	
		_	

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

11.1.	is the	reporting entity organized as:							
	11.12	A Medical Group/Staff Model,						Yes[]	No [X]
	11.13	An Individual Practice Association	ı (IPA), or					Yes[X]	No []
	11.14	A Mixed Model (combination of al	oove)?					Yes[]	No [X]
11.2.	Is the	reporting entity subject to Minimum	n Net Worth Requiremen	nts?				Yes[X]	No[]
11.3.	If yes,	show the name of the state requiri	ng such net worth.	Maine				_	
11.4.	If yes,	show the amount required.						\$	8,112,440
11.5.	Is this	amount included as part of a conti	ngency reserve in stockl	holder's equity?				Yes []	No [X]
11.6.		amount is calculated, show the calculated, show the calculated, show the calculated and the calculated are calculated.		ner Disclosures.					
12.		ervice areas in which reporting entit						-	
	2.00	Name of Servic Androscroggin, Aroostook, Cumb Hancock, Kennebec, Knox, Linco Penobscot, Piscataquis, Sagadał Waldo, Washington, York	e Area erland, Franklin, In, Oxford,						
13.1.	Do vo	u act as a custodian for health savi	ngs account?	_				Yes[]	No [X]
	•	please provide the amount of cust	•	e reporting date.				\$	
	-	u act as an administrator for health		p 3				Yes []	No [X]
	-	please provide the balance of the	•	of the reporting date.				\$	
	-	ny of the captive affiliates reported					Yes[]	No []	N/A [X]
14.2	If the	answer to 14.1 is yes, please provi	de the following:						
		1	2	3	4		sets Supporting Rese	rve Credit	
			NAIC			5	6	7	
			Company	Domiciliary	Reserve	Letters of	Trust		
		Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Oth	
		N/A	0		0	0	0		0
15.	Provid	le the following for Individual Ordin	ary Life insurance* polic	ies (U.S. business only) fo	or the current year (prior	r to reinsurance assu	imed or ceded):		
	15.1	Direct written premium						\$	0
	15.2	Total incured claims						\$	0
	15.3	Number of covered lives							0
			*Ordinary Life Insuran	ce Includes:					
		Term (whether full underwriting, li	mited underwriting, jet is	ssue, "short form app")					
		Whole Life (whether full underwrit	ing, limited underwriting	, jet issue, "short form app	o")				
		Variable Life (with or without second	ondary guarantee)						
		Universal Life (with or without sec	condary guarantee)						
		Variable Universal Life (with or wi	thout secondary guaran	tee)					

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) FIVE-YEAR HISTORICAL DATA

	AK HISTOR	NICAL DAT			_
	1 2014	2013	3 2012	4 2011	5 2010
Balance Sheet Items (Pages 2 and 3)					
Total admitted assets (Page 2, Line 28)	27,908,162	34,153,288	27,596,455	19,390,490	24,212,983
2. Total liabilities (Page 3, Line 24)	12,238,314	20,244,901	12,778,429	8,018,560	9,281,884
3. Statutory surplus	8,112,440	7,599,128	6,619,174	5,396,938	6,481,336
4. Total capital and surplus (Page 3, Line 33)	15,669,848	13,908,387	14,818,026	11,371,930	14,931,099
Income Statement Items (Page 4)					
5. Total revenues (Line 8)	104,717,067	98,278,951	93,218,609	72,745,680	81,739,190
6. Total medical and hospital expenses (Line 18)	91,062,950	84,450,948	72,938,453	57,235,391	70,282,434
7. Claims adjustment expenses (Line 20)	1,591,423	2,421,320	1,934,059	1,561,096	1,693,002
8. Total administrative expenses (Line 21)	12,084,100	11,010,883	8,921,462	7,197,621	7,564,018
9. Net underwriting gain (loss) (Line 24)	2,098,187	(1,640,483)	9,500,331	6,628,684	2,861,464
10. Net investment gain (loss) (Line 27)	718,033	(150,793)	612,022	749,439	1,495,512
11. Total other income (Lines 28 plus 29)	0	0	0	0	0
12. Net income or (loss) (Line 32)	2,559,654	(1,365,571)	7,423,060	5,633,956	4,152,361
Cash Flow (Page 6)					
13. Net cash from operations (Line 11)	(2,650,769)	2,794,884	7,536,528	4,967,206	(670,004
Risk-Based Capital Analysis	, ,				,
14. Total adjusted capital	15,669,848	13,908,387	14,818,026	11,371,930	14,931,099
15. Authorized control level risk-based capital	4,056,220	3,799,564	3,309,587	2,698,469	3,240,668
Enrollment (Exhibit 1)					
16. Total members at end of period (Column 5, Line 7)	12,582	19,302	17,072	12,265	12,236
17. Total member months (Column 6, Line 7)			185,746		
Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3, and 5) x 100 .0					
18. Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19. Total hospital and medical plus other non-health (Line 18 plus Line 19)	87.0	85.9	78.2	78.7	86.0
20. Cost containment expenses	1.1	1.7	1.3	1.4	1.4
21. Other claims adjustment expenses	0.4		0.7	0.7	0.7
22. Total underwriting deductions (Line 23)	98.0	101.7	89.8	90.9	96.5
23. Total underwriting gain (loss) (Line 24)	2.0	(1.7)	10.2	9.1	3.5
Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24. Total claims incurred for prior years (Line 13 Col. 5)	7,978,034	7,994,819	5,526,364	5,769,933	9,294,190
25. Estimated liability of unpaid claims - [prior year (Line 13, Col. 6)]	9,293,699	7,588,075	6,539,214	7,555,655	11,048,792
Investments in Parent, Subsidiaries and Affiliates					
26. Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27. Affiliated preferred stocks (Sch D. Summary, Line 18, Col. 1)	0	0	0	0	0
28. Affiliated common stocks (Sch D. Summary, Line 24, Col. 1)	0	0	0	0	0
29. Affiliated short-term investments (subtotal included in Sch. DA,					
Verification, Column 5, Line 10)	0	0	0	0	0
30. Affiliated mortgage loans on real estate					
31. All other affiliated			0		
32. Total of above Lines 26 to 31			0		
33. Total investment in parent included in Lines 26 to 31 above			0		

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors?

If no, please explain:

Yes [] No []

Statement as of December 31, 2014 of the Aetna Health Inc. (a Maine corporation) SCHEDULE T - PREMIUMS AND OTHER CONSIDERATIONS


Allocated by States and Territories

	i i	1 1		Allocated by		Direct Busi	ness Only			1
	İ	l ' i	2	3	4	5	6 6	7	8	9
	İ	l i	'	I		Federal Employees	Life & Annuity	l '.		ا ۲
1	i	ļ ,	Accident			Health	Premiums and	Property/	Total	Deposit-
1	i	Active	& Health	Medicare	Medicaid	Benefits Plan	Other	Casualty	Columns	Туре
1	State, Etc.	Status	Premiums	Title XVIII	Title XIX	Premiums	Considerations	Premiums	2 Through 7	Contracts
1.	AlabamaAL	N	0	0	0	0	0	0	0	0
	AlaskaAK	N	۱	ا ا	0	l		0	0	١
		N	۱ ا	ا ' ا	0		0	l		
	/ \(\)\(\)\(\)		[1	ا ا		J		I		,U
	ArkansasAR		0	0	0	0	0	0	0	0
	CaliforniaCA	N	0	0	0	J0	0	0	0	ا 0
6.	ColoradoCO	N	0	0	0	J0	0	0	0	0
7.	ConnecticutCT	N	l0 I	l0 l	0	l0	0	0	0	·0
	DelawareDE	N	lnı	ا ۱	0	l	0	0	n	ا <u>ا</u>
	District of ColumbiaDC		0	0	0		0	0	0	۱ ۸
	FloridaFL	N	ر ا م	ر م	0		0	0		۱۸
	- 101100		0	0	0	U	0	0	0	ıU
	000.9	N		0		I	[0		0	0
	HawaiiHI	N	0	0	0	J0	[0 i	0	0	0
-	IdahoID	N	0	0	0	J0	0	0	0	ı0
14.	IllinoisIL	N	0	0	0	ļ0 i	0	0	0	'0
	IndianaIN	N	0	0	0	l0	0	0	0	·0
	lowaIA	N	n l	0	0		0	0	n	ا ۾ا
	KansasKS	N	0	0	0		0	0		ا ۱
	KentuckyKY	N	0	0	0		0	0	0	ı
				•		T0				, j
	LouisianaLA	N	026.064	0	0	J0	0	0	0	,0
	MaineME	[l	42,936,964	62,231,229	0	J0	0	0	105,168,193	0
	MarylandMD	N	0	0	0	J0	0	0	0	ı0
	MassachusettsMA	N	J 1	I0 l	0	[0 ·	0	0	0	·0
	MichiganMI	N	0	0	0	ļ0 :	0	0	0	·0
	MinnesotaMN	N	0	0	0	n	0	0	0	آ ۾ <u>آ</u> ا
	MississippiMS		0	0	0		0	0		ا ۱
	MissouriMO	N		0	0	l ^ '	0	0		
			0	I	0	[0	0	0	0	,U
		N		0		I				0
	NebraskaNE	N	0	0	0	J0	0	0	0	0
	NevadaNV	N	0	0	0	J0	0	0	0	0
30.	New HampshireNH	N	0	0	0	l0	0	0	0	'0 l
	New JerseyNJ	N	0	0	0	l ń	0	0	0	۱
	New MexicoNM	N	0	ا ۱	0		0	0		۱
	New YorkNY	N	0	0	0		0	0	0	U
						T				0
	North CarolinaNC	N	0	0	0	0	0	0	0	,0
	North DakotaND	N	0	0	0	J0	0	0	0	0
	OhioOH		J0 I	0	0	J0	0	0	0	0
	OklahomaOK		0	0	0	[0 i	0	0	0	0
	OregonOR		0	0	0	0	0	0	0	·
	PennsylvaniaPA		0	0	0	0	0	0		0
	Rhode IslandRI		0	0	0	0	0	0	-	0
	South CarolinaSC	N	0	0	0	0	0		0	0
	South DakotaSD		0			0				0
			•	0	0	0	0	0	0	0
	TennesseeTN		0	0	0	0	^	0	0	0
	TexasTX	N	0	0	0	0	0	0	-	0
	UtahUT	N	0	0	0	0	0	0	0	0
46.	VermontVT	N	0	0	0	0	0	0	0	0
	VirginiaVA		0	0	0	0	0	0		0
	WashingtonWA		0	0	0		0	0		ا ا
	West VirginiaWV	N	0	0	0	0			-	·
						0				0
	WisconsinWI	N	0	0	0	0	0	0	0	0
	WyomingWY	N	0	0	0	0	0	0	0	0
	American SamoaAS		0	0	0	0	0	0	0	0
	GuamGU	N	0	0	0	0	0	0		0
54.	Puerto RicoPR		0	0	0	0	0	0		0
	U.S. Virgin IslandsVI	N	0	0	0	0	0	0		0
	Northern Mariana IslandsMP	N	0	0	0	0	0	0		0
	CanadaCAN	N	0	0	0	0	0	0		•
					•	0		-		0
	Aggregate Other alienOT	XXX	0	0	0	0	0	0	-	0
	Subtotal	XXX	42,936,964	62,231,229	0	0	0	0	105,168,193	0
	Reporting entity contributions for	ļ i	[1			[[1		1	
	Employee Benefit Plans	XXX		0	0	0	0	0	0	0
		(a)1	42,936,964	62,231,229	0	0	0	0	105,168,193	0
					ILS OF WRITE-					
58001.			0	DETAI	0	0	0	0	0	0
58001. 58002.		······i	0		0	_		0	0	0
		i		0			0	-	•	-
	Cummany of romaining write inc for liv			0	0	0	0	0		0
	Summary of remaining write-ins for lir			0	0		0	0	-	0
58999.	Total (Lines 58001 thru 58003 + 5899	98)	0	0	0	0	0	0		0
(L) - Lic	censed or Chartered - Licensed Insura	ance Carrier or	- Domiciliad DDC	3 (R) - Registers	ad Non domini	ad PDCs: (O) Ours	lified Ouglified -	r Approality of D	in 0: : ro r:	

⁽a) Insert the number of L responses except for Canada and Other Alien.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP


PART 1 - ORGANIZATIONAL CHART



(1) Insurers/HMO

Percentages are rounded to the nearest whole percent and based on ownership of voting rights. Double borders indicate entity has subsidiaries shown on the same page. Bold borders indicate entity has subsidiaries shown on a separate page.


^{*55%} is owned by AUSHC Holdings, Inc. and 45% is owned by third parties.



^{*}Aetna Global Benefits (Bermuda) Limited owns 80% and 20% is owned by Suhatsyah Rivai, Aetna's Nominee.

** Aetna Global Benefits (Bermuda) Limited owns 49% and 51% is owned by Euro Gulf LLC, Aetna's Nominee.


*** Aetna Global Benefits (Asia Pacific) Limited owns 0.019857% of Indian Health Organization Private Limited and Aetna Global Benefits (Singapore) Pte. Ltd. owns 99.980143%.





^{*} Aetna Life Insurance Company owns 302 shares, Aetna Health Inc. (PA) owns 198 shares and Aetna Health Holdings, LLC owns 1 share.
** Innovation Health Holdings, LLC is 50% owned by Aetna ACO Holdings, Inc. and 50% owned by Inova Health System Foundation, an unaffiliated company.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART








^{*} Aetna Life Insurance Company owns the Class C participating shares of Aetna Partners Diversified Fund (Cayman), Limited.


^{**} Aetna Life Insurance Company and Aetna Health and Life Insurance Company own substantially all of the non-managing member interests of Aetna Partners Diversified Fund, LLC.



^{*} Aetna Life Insurance Company owns 302 shares, Aetna Health Inc. (PA) owns 198 shares and Aetna Health Holdings, LLC owns 1 share.

^{**} Innovation Health Holdings, LLC is 50% owned by Aetna ACO Holdings, Inc. and 50% owned by Inova Health System Foundation, an unaffiliated company.

***78% is invested and owned by Aetna Life Insurance Company and 22% is invested and owned by external accredited investors.



2014 ALPHABETICAL INDEX HEALTH ANNUAL STATEMENT BLANK

Analysis of Operations By Lines of Business	7	Schedule D – Part 6 – Section 2	E16
Assets	2	Schedule D – Summary By Country	SI04
Cash Flow	6	Schedule D – Verification Between Years	SI03
Exhibit 1 – Enrollment By Product Type for Health Business Only	17	Schedule DA – Part 1	E17
Exhibit 2 – Accident and Health Premiums Due and Unpaid	18	Schedule DA - Verification Between Years	SI10
Exhibit 3 – Health Care Receivables	19	Schedule DB – Part A – Section 1	E18
Exhibit 3A - Health Care Receivables Collected and Accrued	20	Schedule DB – Part A – Section 2	E19
Exhibit 4 - Claims Unpaid and Incentive Pool, Withhold and Bonus	21	Schedule DB – Part A – Verification Between Years	SI11
Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates	22	Schedule DB – Part B – Section 1	E20
Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates	23	Schedule DB – Part B – Section 2	E21
Exhibit 7 – Part 1 – Summary of Transactions With Providers	24	Schedule DB – Part B – Verification Between Years	SI11
Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries	24	Schedule DB – Part C – Section 1	SI12
Exhibit 8 – Furniture, Equipment and Supplies Owned	25	Schedule DB – Part C – Section 2	SI13
Exhibit of Capital Gains (Losses)	15	Schedule DB – Part D – Section 1	E22
Exhibit of Net Investment Income	15	Schedule DB – Part D – Section 2	E23
Exhibit of Nonadmitted Assets	16	Schedule DB – Verification	SI14
Exhibit of Premiums, Enrollment and Utilization (State Page)	30	Schedule DL – Part 1	E24
Five-Year Historical Data	29	Schedule DL – Part 2	E25
General Interrogatories	27	Schedule E – Part 1 – Cash	E26
Jurat Page	1	Schedule E – Part 2 – Cash Equivalents	E27
Liabilities, Capital and Surplus	3	Schedule E – Part 3 – Special Deposits	E28
Notes To Financial Statements	26	Schedule E – Verification Between Years	SI15
Overflow Page For Write-ins	44	Schedule S – Part 1 – Section 2	31
Schedule A – Part 1	E01	Schedule S – Part 2	32
Schedule A – Part 2	E02	Schedule S – Part 3 – Section 2	33
Schedule A – Part 3	E03	Schedule S – Part 4	34
Schedule A – Verification Between Years	SI02	Schedule S – Part 5	35
Schedule B – Part 1	E04	Schedule S – Part 6	36
Schedule B – Part 2	E05	Schedule S – Part 7	37
Schedule B – Part 3	E06	Schedule T – Part 2 – Interstate Compact	38
Schedule B – Verification Between Years	SI02	Schedule T – Premiums and Other Considerations	39
Schedule BA – Part 1	E07	Schedule Y – Information Concerning Activities of Insurer Members of a Holding Company Group	40
Schedule BA – Part 2	E08	Schedule Y – Part 1A – Detail of Insurance Holding Company System	41
Schedule BA – Part 3	E09	Schedule Y – Part 2 – Summary of Insurer's Transactions With Any Affiliates	42
Schedule BA – Verification Between Years	SI03	Statement of Revenue and Expenses	4
Schedule D – Part 1	E10	Summary Investment Schedule	SI01
Schedule D – Part 1A – Section 1	SI05	Supplemental Exhibits and Schedules Interrogatories	43
Schedule D – Part 1A – Section 2	SI08	Underwriting and Investment Exhibit – Part 1	8
Schedule D – Part 2 – Section 1	E11	Underwriting and Investment Exhibit – Part 2	9
Schedule D – Part 2 – Section 2	E12	Underwriting and Investment Exhibit – Part 2A	10
Schedule D – Part 3	E13	Underwriting and Investment Exhibit – Part 2B	11
Schedule D – Part 4	E14	Underwriting and Investment Exhibit – Part 2C	12
Schedule D – Part 5	E15	Underwriting and Investment Exhibit – Part 2D	13
Schedule D – Part 6 – Section 1	E16	Underwriting and Investment Exhibit – Part 3	14
	-	· · · · · ·	